<SEC-DOCUMENT>0001193125-25-236064.txt : 20251009
<SEC-HEADER>0001193125-25-236064.hdr.sgml : 20251009
<ACCEPTANCE-DATETIME>20251009171719
ACCESSION NUMBER:		0001193125-25-236064
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20251007
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251009
DATE AS OF CHANGE:		20251009

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MANNKIND CORP
		CENTRAL INDEX KEY:			0000899460
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				133607736
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50865
		FILM NUMBER:		251385860

	BUSINESS ADDRESS:	
		STREET 1:		1 CASPER STREET
		CITY:			DANBURY
		STATE:			CT
		ZIP:			06810
		BUSINESS PHONE:		818-661-5000

	MAIL ADDRESS:	
		STREET 1:		1 CASPER STREET
		CITY:			DANBURY
		STATE:			CT
		ZIP:			06810
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d63266d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mnkd="http://www.mannkindcorp.com/20251007" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2025-10-07_to_2025-10-07">MANNKIND CORP</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-402">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-10-07_to_2025-10-07">0000899460</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="mnkd-20251007.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-10-07_to_2025-10-07"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000899460</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-10-07</xbrli:startDate> <xbrli:endDate>2025-10-07</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-413">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-10-07_to_2025-10-07" format="ixt:datemonthdayyearen" id="ixv-414">October&#160;7, 2025</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">MannKind Corporation</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-10-07_to_2025-10-07" format="ixt-sec:stateprovnameen" id="ixv-415">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-416">000-50865</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-417">13-3607736</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-418">1 Casper Street</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-419">Danbury</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-10-07_to_2025-10-07" format="ixt-sec:stateprovnameen" id="ixv-420">Connecticut</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-421">06810</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of Principal Executive Offices, including Zip Code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-422">(818)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-423">661-5000</ix:nonNumeric></span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address if changed since last report.)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-10-07_to_2025-10-07" format="ixt-sec:boolballotbox" id="ixv-424">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-10-07_to_2025-10-07" format="ixt-sec:boolballotbox" id="ixv-425">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-10-07_to_2025-10-07" format="ixt-sec:boolballotbox" id="ixv-426">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-10-07_to_2025-10-07" format="ixt-sec:boolballotbox" id="ixv-427">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-428">Common Stock, par value $0.01 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-429">MNKD</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-10-07_to_2025-10-07" format="ixt-sec:exchnameen" id="ixv-430">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging Growth Company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-10-07_to_2025-10-07" format="ixt-sec:boolballotbox" id="ixv-431">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Introductory Note. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously disclosed in the Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the Securities and Exchange Commission (&#8220;<span style="text-decoration:underline">SEC</span>&#8221;) by MannKind Corporation, a Delaware corporation (the &#8220;<span style="text-decoration:underline">Company</span>&#8221;) on August&#160;25, 2025, the Company entered into an Agreement and Plan of Merger (the &#8220;<span style="text-decoration:underline">Merger Agreement</span>&#8221;), dated as of August&#160;24, 2025, with Seacoast Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (&#8220;<span style="text-decoration:underline">Purchaser</span>&#8221;), and scPharmaceuticals Inc., a Delaware corporation (&#8220;<span style="text-decoration:underline">scPharma</span>&#8221;). Pursuant to the Merger Agreement, on September&#160;8, 2025, the Company, through Purchaser, commenced a tender offer to purchase all the outstanding shares of scPharma&#8217;s common stock, par value $0.0001 per share (the &#8220;<span style="text-decoration:underline">scPharma Shares</span>&#8221;), at a price per share of (i) $5.35 in cash (the &#8220;<span style="text-decoration:underline">Cash Amount</span>&#8221;), without interest, subject to any applicable withholding taxes and (ii)&#160;one <span style="white-space:nowrap">non-tradable</span> contingent value right (each, a &#8220;<span style="text-decoration:underline">CVR</span>&#8221;) per scPharma Share, which represents the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash, without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates in accordance with the terms and conditions set forth in the Contingent Value Rights Agreement (the &#8220;<span style="text-decoration:underline">CVR Agreement</span>&#8221;), entered into with Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company (the &#8220;<span style="text-decoration:underline">Rights Agent</span>&#8221;) (the Cash Amount plus the CVR, collectively, the &#8220;<span style="text-decoration:underline">Offer Price</span>&#8221;), upon the terms and subject to the conditions set forth in the Offer to Purchase, dated September&#160;8, 2025 (together with any amendments or supplements thereto, the &#8220;<span style="text-decoration:underline">Offer to Purchase</span>&#8221;), in the related Letter of Transmittal (together with any amendments or supplements thereto, the &#8220;<span style="text-decoration:underline">Letter of Transmittal</span>&#8221;) and the related Notice of Guaranteed Delivery (together with any amendments or supplements thereto, the &#8220;<span style="text-decoration:underline">Notice of Guaranteed Delivery</span>&#8221; and, the Offer to Purchase, the Letter of Transmittal and the Notice of Guaranteed Delivery, collectively, the &#8220;<span style="text-decoration:underline">Offer</span>&#8221;). The Offer to Purchase, the Letter of Transmittal and Notice of Guaranteed Delivery were filed as Exhibits (a)(1)(i), (a)(1)(ii) and (a)(1)(iii), respectively, to the Tender Offer Statement on Schedule TO originally filed with the SEC by Purchaser and the Company on September&#160;8, 2025. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Contingent Value Rights Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, on October&#160;7, 2025, the Company and the Rights Agent entered into the Contingent Value Rights Agreement (the &#8220;<span style="text-decoration:underline">CVR Agreement</span>&#8221;) governing the terms of the CVRs issued pursuant to the Offer and the Merger (as defined below). The Rights Agent will <span style="white-space:nowrap"><span style="white-space:nowrap">maintain&#160;an&#160;up-to-date&#160;register&#160;of</span></span> the holders of CVRs (the &#8220;<span style="text-decoration:underline">Holders</span>&#8221;).&#160;Holders will not be permitted to transfer the CVRs (subject to certain limited exceptions as set forth in the CVR Agreement). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each CVR represents the right to receive the following contingent cash payments, without interest, subject to any applicable withholding taxes (each, a &#8220;<span style="text-decoration:underline">Milestone Payment</span>&#8221;), conditioned upon the achievement of the following milestone conditions within the following specified time periods: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(i)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Milestone 1 &#8212; Receipt of U.S. Food and Drug Administration (&#8220;<span style="text-decoration:underline">FDA</span>&#8221;) approval of a drug-device combination product comprising <span style="white-space:nowrap">SCP-111</span> delivered either in an autoinjector or scPharma&#8217;s device supplier-developed Self-Dose injection delivery system (such product, an &#8220;<span style="text-decoration:underline">Injection Product</span>&#8221; and, such milestone, &#8220;<span style="text-decoration:underline">Milestone 1</span>&#8221;) with (a)&#160;$0.75&#160;per CVR if Milestone 1 is achieved by September&#160;30, 2026, (b) $0.50 per CVR if Milestone 1 is achieved by December&#160;31, 2026 and (c) $0.25&#160;per CVR if Milestone 1 is achieved by June&#160;30, 2027 (the &#8220;<span style="text-decoration:underline">Milestone 1 Outside Date</span>&#8221;). Milestone 1 will not be achieved if FDA approval occurs after the Milestone 1 Outside Date; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(ii)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Milestone 2 &#8212; Achievement in any trailing consecutive <span style="white-space:nowrap">12-month</span> period ending prior to and including December&#160;31, 2026 (the &#8220;<span style="text-decoration:underline">Milestone 2 Outside Date</span>&#8221; and, together with the Milestone 1 Outside Date, the &#8220;<span style="text-decoration:underline">Milestone Outside Dates</span>&#8221;) of at least $110.0&#160;million of worldwide net sales of all Injection Products and FUROSCIX<sup style="font-size:75%; vertical-align:top">&#174;</sup>&#160;Infusors (collectively, the &#8220;<span style="text-decoration:underline">Products</span>&#8221;) in such <span style="white-space:nowrap">12-month</span> period </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top;text-align:left">
(&#8220;<span style="text-decoration:underline">Milestone</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2</span>&#8221; and, together with Milestone 1, the &#8220;<span style="text-decoration:underline">Milestones</span>&#8221;) with (a) $0.25 per CVR upon the achievement of $120.0&#160;million of worldwide net sales in such period and (b)&#160;between $0.10 and $0.25&#160;per CVR if, as of December&#160;31, 2026, the highest worldwide net sales in any trailing <span style="white-space:nowrap">12-month</span> period were between $110.0&#160;million and $120.0&#160;million, which payment will be calculated on a straight-line basis such that the payment per CVR increases proportionally as worldwide net sales increase from $110.0&#160;million to $120.0&#160;million. Milestone&#160;2 will not be achieved if trailing worldwide net sales are less than $110&#160;million during this period. </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to each Milestone, until the earlier of the date on which such Milestone has been achieved and the applicable Milestone Outside Date, as applicable, the Company (directly or through its assignees or their respective affiliates or certain sublicensees of any of the foregoing) is obligated to use certain specified commercially reasonable efforts to achieve such Milestone. There can be no assurance that either Milestone 1 or Milestone 2 will be achieved on or before the applicable Milestone Outside Date or that any Milestone Payments will be made. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the CVR Agreement is not complete and is qualified in its entirety by reference to the CVR Agreement, a copy of which is attached hereto as <span style="text-decoration:underline">Exhibit 10.1</span> and incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;2.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Completion of Acquisition or Disposition of Assets. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth in the Introductory Note and Items 1.01 and 2.03 of this Current Report on Form <span style="white-space:nowrap">8-K</span> is incorporated by reference into this Item 2.01. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offer and related withdrawal rights expired as scheduled at one minute after 11:59 p.m., Eastern time, on October&#160;6, 2025 (such date and time, the &#8220;<span style="text-decoration:underline">Expiration Date</span>&#8221;). Purchaser was advised by&#160;Broadridge Corporate Issuer Solutions, LLC, the depositary for the Offer, that as of the Expiration Date, a total of 39,933,692 scPharma Shares (excluding any scPharma Shares tendered pursuant to guaranteed delivery procedures that had not yet been &#8220;received,&#8221; as such term is defined by Section&#160;251(h) of the Delaware General Corporation Law (the &#8220;<span style="text-decoration:underline">DGCL</span>&#8221;)) had been validly tendered (and not validly withdrawn) pursuant to the Offer, representing approximately 73.47% of the issued and outstanding scPharma Shares as of the Expiration Date. In addition, Notices of Guaranteed Delivery had been delivered for 5,930,025 scPharma Shares, representing approximately 10.91% of the issued and outstanding scPharma Shares as of the Expiration Date. As of the Expiration Date, the number of scPharma Shares validly tendered and not validly withdrawn pursuant to the Offer satisfied the Minimum Condition (as defined in the Merger Agreement), and all other conditions to the Offer were satisfied. Promptly after the Expiration Date, Purchaser irrevocably accepted for payment all scPharma Shares validly tendered and not validly withdrawn pursuant to the Offer and payment of the Offer Price for such Shares was made promptly in accordance with the terms of the Offer and the Merger Agreement. The Company completed the acquisition of scPharma on October&#160;7, 2025, by causing Purchaser to merge with and into scPharma (the &#8220;<span style="text-decoration:underline">Merger</span>&#8221;) pursuant to the Merger Agreement without any action by scPharma stockholders in accordance with Section&#160;251(h) of the DGCL. At the effective time of the Merger (the &#8220;<span style="text-decoration:underline">Effective Time</span>&#8221;), Purchaser was merged with and into scPharma, the separate existence of Purchaser ceased and scPharma continued as a direct wholly owned subsidiary of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Effective Time, each scPharma Share issued and outstanding immediately prior to the Effective Time (other than scPharma Shares owned by scPharma, the Company or Purchaser or by any of their respective subsidiaries (or held in scPharma&#8217;s treasury), which were cancelled and ceased to exist, and no consideration was delivered in exchange therefor) was cancelled and ceased to exist, and (other than any Shares held by holders who were entitled to appraisal rights under Section&#160;262 of the DGCL and who properly exercised and perfected such holder&#8217;s respective demands for appraisal and, as of the Effective Time, had not effectively withdrawn or lost such holder&#8217;s rights to such appraisal and payment under the DGCL), and was converted into the right to receive the Offer Price, without interest, subject to any applicable withholding of taxes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, by virtue of the Merger, without any action on the part of scPharma, the Company or the holder thereof: (i)&#160;each option to purchase scPharma Shares (each, an &#8220;<span style="text-decoration:underline">scPharma Option</span>&#8221;) that was outstanding and unexercised as of immediately prior to the Effective Time and that did not have an exercise price per scPharma Share that is equal to or greater than the Cash Amount, whether or not then vested or exercisable, was canceled and converted into the right to receive (x)&#160;an amount in cash, </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
without interest and subject to any applicable withholding taxes, equal to the product obtained by multiplying (A)&#160;the total number of scPharma Shares subject to such scPharma Option immediately prior to such cancellation by (B)&#160;the excess, if any, of (1)&#160;the Cash Amount over (2)&#160;the exercise price payable per scPharma Share underlying such scPharma Option and (y)&#160;one CVR in respect of each scPharma Share subject to such Company Option, and (ii)&#160;each restricted stock unit award with respect to scPharma Shares (each, an &#8220;<span style="text-decoration:underline">scPharma RSU Award</span>&#8221;) that was outstanding immediately prior to the Effective Time, whether or not then vested, fully vested and was canceled and converted into the right to receive (x)&#160;an amount in cash, without interest and subject to any applicable withholding taxes, equal to the product obtained by multiplying (A)&#160;the number of scPharma Shares subject to such scPharma RSU Award immediately prior to such cancellation, by (B)&#160;the Cash Amount and (y)&#160;one CVR in respect of each scPharma Share subject to such scPharma RSU Award. All amounts payable to current or former scPharma employees with respect to scPharma Options and scPharma RSU Awards will be paid as soon as reasonably practicable after the Effective Time (but no later than fifteen (15)&#160;days after the Effective Time) and will be subject to deduction for any required tax withholding. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All warrants to purchase scPharma Shares (&#8220;<span style="text-decoration:underline">scPharma Warrants</span>&#8221;) were exercised prior to the Effective Time, and the scPharma Shares underlying such exercised scPharma Warrants were treated in the same manner as each scPharma Share outstanding immediately prior to the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate cash paid by the Company and Purchaser in the Offer and the Merger at the Closing Date was approximately $296.5&#160;million (the &#8220;<span style="text-decoration:underline">Acquisition Price</span>&#8221;), which was funded by the Company from its available cash on hand and net proceeds from borrowings under its Credit Agreement (as defined below). As described below in Item 2.03, the Company also funded the scPharma Debt Extinguishment (as defined below) totaling approximately $82.6&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Offer, the Merger, the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, a copy of which is attached hereto as <span style="text-decoration:underline">Exhibit 2.1</span> and incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;2.03</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Creation of a Direct Financial Obligation or an Obligation under an <span style="white-space:nowrap">Off-Balance</span> Sheet Arrangement of a Registrant. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously disclosed, on August&#160;24, 2025, the Company entered into Amendment No.&#160;1 to Loan Agreement and Security Agreement (the &#8220;<span style="text-decoration:underline">Credit Agreement Amendment</span>&#8221;) with Blackstone Alternative Credit Advisors LP, as Blackstone Representative (in such capacity, &#8220;<span style="text-decoration:underline">Blackstone</span>&#8221;), the lenders party thereto (the &#8220;<span style="text-decoration:underline">Lenders</span>&#8221;), the subsidiary guarantors party thereto, and Wilmington Trust, National Association, as administrative agent and collateral agent for the lenders (in such capacity, the &#8220;<span style="text-decoration:underline">Agent</span>&#8221;), which amended that certain Loan Agreement (the &#8220;<span style="text-decoration:underline">Original Credit Agreement</span>&#8221;, and the Original Credit Agreement as amended by the Credit Agreement Amendment, the &#8220;<span style="text-decoration:underline">Credit Agreement</span>&#8221; and, the credit facility provided for thereunder, the &#8220;<span style="text-decoration:underline">Blackstone Credit Facility</span>&#8221;), dated August&#160;6, 2025, among the Company, Blackstone, the lenders party thereto from time to time, the subsidiary guarantors party thereto from time to time, and Agent. Pursuant to the Credit Agreement Amendment, among other things, the Lenders agreed to provide an additional $175.0&#160;million incremental delayed draw term loan solely to finance a portion of the fees, premiums, expenses and other transaction costs incurred in connection with the transactions contemplated by the Merger Agreement (the &#8220;<span style="text-decoration:underline">Transaction Funding</span>&#8221;), subject to certain customary draw down conditions as set forth in the Credit Agreement Amendment. In addition, pursuant to the Credit Agreement Amendment, the Lenders agreed to limit the conditions precedent to the Company&#8217;s borrowing of up to $75.0&#160;million of delayed draw term loans (out of the aggregate $125.0&#160;million in delayed draw term loan commitments available under the Original Credit Agreement) to certain customary draw down conditions as set forth in the Credit Agreement Amendment to the extent such loans are used solely for the Transaction Funding. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a condition to providing the Transaction Funding, upon the closing of the Merger, the Company was required to (i)&#160;repay and extinguish all outstanding indebtedness of scPharma under that certain Credit Agreement and Guaranty (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the &#8220;<span style="text-decoration:underline">Existing Perceptive Credit Agreement</span>&#8221;), dated as of August&#160;9, 2024, by and among scPharma, the guarantors from time to time party thereto, the lenders from time to time party thereto and Perceptive Credit Holdings IV, LP (&#8220;<span style="text-decoration:underline">Perceptive</span>&#8221;), in its capacity as administrative agent for the lenders and (ii)&#160;repurchase Perceptive&#8217;s rights to receive revenue payments pursuant to that certain Revenue Participation </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Right Purchase and Sale Agreement (the &#8220;<span style="text-decoration:underline">Existing Perceptive RIF Agreement</span>&#8221;), dated as of August&#160;9, 2024, by and between scPharma, as seller, and Perceptive, as buyer (such repayment, extinguishment and repurchase described in the preceding clauses (i)&#160;and (ii), the &#8220;<span style="text-decoration:underline">scPharma Debt Extinguishment</span>&#8221;), which scPharma Debt Extinguishment totaled an aggregate repayment and repurchase amount of approximately $82.6&#160;million. Upon the scPharma Debt Extinguishment, each of the Existing Perceptive Credit Agreement and the Existing Perceptive RIF Agreement were terminated. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;7, 2025, the Company borrowed $250.0&#160;million in delayed draw term loans to fund the Acquisition Price and the scPharma Debt Extinguishment. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Blackstone Credit Facility will mature on August&#160;6, 2030. The loans thereunder bear interest at a rate per annum equal to one, three or six month term SOFR (at the Company&#8217;s election), subject to a 2% floor, plus a margin of 4.75%. Interest is paid quarterly or, if the Company elects <span style="white-space:nowrap">one-month</span> SOFR, monthly. The interest rate margin increases to 5.00% at any time the Company&#8217;s ratio of indebtedness to adjusted EBITDA (measured on a trailing four quarter basis) is greater than or equal to 5.00:1.00 as of the most recent fiscal quarter for which the Company has delivered financial statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Credit Agreement Amendment does not purport to be complete and is qualified in its entirety by reference to the Credit Agreement Amendment, a copy of which is attached hereto as <span style="text-decoration:underline">Exhibit 10.2</span> and incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Financial Statements of Business Acquired </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements required by this Item 9.01(a) will be filed by amendment to this Current Report on Form <span style="white-space:nowrap">8-K</span> not later than 71 calendar days after the date on which this Current Report on Form <span style="white-space:nowrap">8-K</span> is required to be filed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Pro Forma Financial Information </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information of the Company as of and for the six months ended June&#160;30, 2025 and the year ended December&#160;31, 2024 required by this Item 9.01(b) will be filed by amendment to this Current Report on Form <span style="white-space:nowrap">8-K</span> not later than 71 calendar days after the date on which this Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;is</span> required to be filed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;2.1*#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/899460/000119312525186994/d931701dex21.htm">Agreement and Plan of Merger, dated August&#160;24, 2025, by and among MannKind Corporation, Seacoast Merger Sub, Inc. and scPharmaceuticals Inc. (incorporated by reference to Exhibit&#160;2.1 to MannKind Corporation&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;000-50865),</span> filed with the SEC on August&#160;25, 2025).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d63266dex101.htm">Contingent Value Rights Agreement, dated as of October&#160;7, 2025, by and between MannKind Corporation and Broadridge Corporate Issuer Solutions, LLC. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0000899460/000119312525186994/d931701dex102.htm">Amendment No.1 to the Loan Agreement, dated August&#160;24, 2025, among MannKind Corporation, certain subsidiaries of MannKind Corporation, Wilmington Trust, National Association, Blackstone Alternative Credit Advisors LP and the lenders from time to time party thereto (incorporated by reference to Exhibit&#160;10.2 to MannKind Corporation&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (file <span style="white-space:nowrap">No.&#160;000-50865),</span> filed with the SEC on August&#160;25, 2025).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Previously filed. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">**</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Filed herewith. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">#</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain annexes, exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation <span style="white-space:nowrap">S-K.</span> The registrant hereby undertakes to furnish supplemental copies of any of the omitted annexes and schedules upon request by the SEC. </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: October&#160;9, 2025 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0;margin-left:auto">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">MANNKIND CORPORATION</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">/s/ Michael E. Castagna</span></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael E. Castagna</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Executive Officer</span></p></td></tr>
</table></div>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d63266dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONTINGENT VALUE RIGHTS AGREEMENT </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS
CONTINGENT VALUE RIGHTS AGREEMENT (this &#8220;<U>Agreement</U>&#8221;) dated as of October&nbsp;7, 2025, between MannKind Corporation, a Delaware corporation (&#8220;<U>Parent</U>&#8221;), and Broadridge Corporate Issuer Solutions, LLC, a
Pennsylvania limited liability company, as Rights Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>I<SMALL>NTRODUCTION</SMALL> </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Parent, Seacoast Merger Sub, Inc., a Delaware corporation (&#8220;<U>Purchaser</U>&#8221;), and scPharmaceuticals Inc., a Delaware
corporation (the &#8220;<U>Company</U>&#8221;), have entered into an Agreement and Plan of Merger dated as of August 24, 2025 (as it may be amended or supplemented from time to time pursuant to the terms thereof, the &#8220;<U>Merger
Agreement</U>&#8221;), pursuant to which (a)&nbsp;Purchaser has made a tender offer (as it may be amended, modified or extended from time to time as permitted under the Merger Agreement, the &#8220;<U>Offer</U>&#8221;) to acquire all of the
outstanding shares of common stock, par value $0.0001 per share, of the Company (such shares, collectively, the &#8220;<U>Company</U> <U>Shares</U>&#8221;) and (b)&nbsp;following the acceptance for payment of Company Shares pursuant to the Offer,
Purchaser will merge with and into the Company (the &#8220;<U>Merger</U>&#8221;), with the Company continuing as the surviving corporation in the Merger as a direct wholly owned subsidiary of Parent; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to the terms of the Merger Agreement, as a result of the consummation of the Offer or the Merger, as the case may be, the
holders of Company Shares as of immediately prior to the Effective Time and holders of In the Money Options and Company RSU Awards (each as defined below) as of immediately prior to the Effective Time will become entitled to receive two contingent
cash payments, as hereinafter described upon the achievement of the applicable milestones, as hereinafter described; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
pursuant to this Agreement, the maximum potential amount payable per CVR (as defined below) is one dollar ($1.00) in cash, without interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing and the consummation of the transactions referred to above, Parent and Rights Agent agree,
for the equal and proportionate benefit of all Holders (as defined below), as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 1 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">DEFINITIONS; CERTAIN RULES OF CONSTRUCTION </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1 <U>Definitions</U>. As used in this Agreement, the following terms will have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Accounting Standards</U>&#8221; means, with respect to a Person, (a)&nbsp;United States Generally Accepted Accounting Principles or
(b)&nbsp;International Financial Reporting Standards as issued by the International Accounting Standards Board, as consistently applied by such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Acting Holders</U>&#8221; means, at the time of determination, Holders of not less than a majority of the outstanding CVRs as set
forth in the CVR Register. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Affiliate</U>&#8221; means, with respect to any Person, any other Person which
directly or indirectly controls, is controlled by or is under common control with such Person. For purposes of the immediately preceding sentence, the term &#8220;control&#8221; (including, with correlative meanings, the terms
&#8220;controlling,&#8221; &#8220;controlled by&#8221; and &#8220;under common control with&#8221;), as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of management or
policies of such Person, whether through the ownership of securities, partnership or other ownership interests, by contract or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Assignee</U>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Business Day</U>&#8221; means any day other than (a)&nbsp;a Saturday or a Sunday or (b)&nbsp;a day on which banking and savings and
loan institutions are authorized or required by applicable Law to be closed in the State of New York (including New York Stock Exchange holidays). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Change of Control Transaction</U>&#8221; shall mean (a)&nbsp;any transaction or series of related transactions (including a tender
offer, merger, consolidation or other business combination) the result of which is that holders of outstanding voting capital stock of Parent immediately prior to such transaction or series of related transactions hold, directly or indirectly,
capital stock of the surviving person in such transaction or series of related transactions (or any ultimate parent thereof) representing less than 50% of the voting power of all outstanding capital stock of such surviving Person (or such ultimate
parent) immediately after such transaction or series of related transactions or (b)&nbsp;the sale, lease, transfer or other disposition of all or substantially all of Parent&#8217;s assets, other than to any subsidiary or subsidiaries of Parent.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Code</U>&#8221; shall have the meaning assigned to such term in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Commercially Reasonable Efforts</U>&#8221; means the level of efforts that is consistent with the </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">level of efforts at least commensurate with the level of efforts that Parent typically devotes in the performance of a corresponding activity for its own
internally developed or <FONT STYLE="white-space:nowrap">in-licensed</FONT> products which are at a similar stage in development and have a similar market potential as the applicable Product (&#8220;<U>Relevant Product</U>&#8221;), taking into
account all scientific, commercial and other relevant factors that Parent would typically take into account with any Relevant Product, including patent coverage, expiration and term extension, regulatory and other exclusivity, manufacturing and
supply chain, product profile, safety and efficacy, actual and anticipated product labeling, the competitiveness of alternative products in the marketplace or under development, actual and anticipated market conditions, geographic market, the
regulatory structure involved and the cost and likelihood of obtaining Regulatory Approval, the legal and regulatory environment, pricing and the availability of coverage and reimbursement and the expected profitability of the applicable product,
including actual and expected development costs and timelines, cost of goods and all other costs associated with the applicable product and timelines associated with commercial entry; provided that, notwithstanding the foregoing, such level of
efforts and resources shall be determined without taking into account the Milestone Payment payable in accordance with, and subject to, the terms hereof. It is understood that product potential (which includes the foregoing factors) may change from
time to time based upon changing scientific, legal and regulatory, business and marketing and/or return on investment considerations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Company Intellectual Property Rights</U>&#8221; shall have the meaning assigned to such term in the Merger Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Company Option</U>&#8221; shall have the meaning assigned to such term in the
Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Company RSU Awards</U>&#8221; shall have the meaning assigned to such term in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Company Stock Awards</U>&#8221; shall have the meaning assigned to such term in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>CVRs</U>&#8221; means the rights of Holders to receive contingent cash payments with respect to Milestone 1 and Milestone 2 pursuant
to the Merger Agreement and this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>CVR Register</U>&#8221; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.3(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>DTC</U>&#8221; means The Depository Trust Company or any successor thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Effective Time</U>&#8221; shall have the meaning assigned to such term in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Entity</U>&#8221; means any corporation (including any <FONT STYLE="white-space:nowrap">non-profit</FONT> corporation), general
partnership, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">limited partnership, limited liability partnership, joint venture, estate, trust, company (including any company limited by shares, limited
liability company or joint stock company), firm, society or other enterprise, association, organization or entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Equity Award
Holder</U>&#8221; means the Holders of CVRs granted with respect to In the Money Options and Company RSU Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>FDA</U>&#8221;
means the United States Food and Drug Administration, or any successor thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Governmental Authority</U>&#8221; means
(a)&nbsp;any government, (b)&nbsp;any governmental, quasi- governmental or regulatory entity, body, department, commission, subdivision, board, administrative agency or instrumentality, (c)&nbsp;any court, tribunal, judicial body, or an arbitrator
or arbitration panel, or (d)&nbsp;any <FONT STYLE="white-space:nowrap">non-governmental</FONT> self-regulatory agency, securities exchange, commission or authority, in each of (a)&nbsp;through (d) whether supranational, national, federal, state,
county, municipal, provincial, and whether local, domestic or foreign. For the avoidance of doubt, Governmental Authority includes the FDA and any other domestic or foreign entity that regulates or has jurisdiction over the quality, identity,
strength, purity, safety, efficacy, testing, manufacturing, marketing, distribution, sale, storage, pricing, import or export of any Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Holder</U>&#8221; means a Person in whose name a CVR is registered in the CVR Register at the applicable time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>IND</U>&#8221; means an investigational new drug application submitted to the FDA pursuant to 21 C.F.R. &#167;312 before
commencement of clinical trials of a pharmaceutical product in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Incidental Contracts</U>&#8221; shall have
the meaning assigned to such term in the Merger Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Injection Product</U>&#8221; means the drug-device combination product comprising
80 mg/1mL FUROSCIX<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (furosemide injection) as described in IND158047, also known as <FONT STYLE="white-space:nowrap">SCP-111,</FONT> delivered either in an autoinjector or the West
Pharmaceuticals-developed Self-Dose injection delivery system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>In the Money Options</U>&#8221; means each Company Option that
is not an Out of the Money Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Law</U>&#8221; shall have the meaning assigned to such term in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Milestone 1</U>&#8221; means the first achievement by a Selling Entity of Regulatory Approval of an Injection Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Milestone 2</U>&#8221; means, in any trailing consecutive twelve (12)-month period ending prior to and including December&nbsp;31,
2026, the achievement of at least $110,000,000 of worldwide Net Sales of all Products in such twelve (12)-month period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Milestone Notice</U>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.4(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Milestone Notice Date</U>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.4(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Milestone Outside Date</U>&#8221; means (a)&nbsp;with respect to Milestone 1, June&nbsp;30, 2027; and (b)&nbsp;with respect to
Milestone 2, December&nbsp;31, 2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Milestone Payment</U>&#8221; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) with respect to Milestone 1, (i) $0.75 without interest, if Milestone 1 is achieved by September 30, 2026, (ii) $0.50 without interest, if
Milestone 1 is achieved by December 31, 2026, and (iii) $0.25 without interest, if Milestone 1 is achieved by June&nbsp;30, 2027; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
with respect to Milestone 2, (i) an amount equal to $0.25 without interest per CVR upon the achievement of $120,000,000 of worldwide Net Sales in any trailing twelve (12)-month period prior to December 31, 2026, and (ii)&nbsp;if, as of December 31,
2026, the highest worldwide Net Sales in any trailing <FONT STYLE="white-space:nowrap">12-month</FONT> period were between $110,000,000 and $120,000,000, a payment per CVR calculated on a straight-line basis between $0.10 and $0.25, such that the
payment per CVR increases proportionally as worldwide Net Sales increase from $110,000,000 to $120,000,000. For the avoidance of doubt, no payment shall be made if the highest worldwide Net Sales in any trailing
<FONT STYLE="white-space:nowrap">12-month</FONT> period are less than $110,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Milestone Payment Amount</U>&#8221; means,
for a given Holder and achievement of a given Milestone (if at all), a <FONT STYLE="white-space:nowrap">one-time</FONT> payment equal to the product of (a)&nbsp;the applicable Milestone Payment for such Milestone and (b)&nbsp;the number of CVRs with
respect to such Milestone held by such Holder as reflected on the CVR Register as of 5:00 p.m., Eastern time, on the applicable Milestone Notice Date for such Milestone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Milestone Payment Date</U>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.4(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Milestones</U>&#8221; means Milestone 1 and Milestone 2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>NDA</U>&#8221; means a new drug application submitted to the FDA under 21 U.S.C.
335(b) for approval to market and commercialize a drug product in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Net Sales</U>&#8221; means the net sales
recorded by any Selling Entity for the sale or disposition of Products in the United States to third parties in <I>bona fide </I>arm&#8217;s length transactions, as determined in accordance with Accounting Standards and as reported in such Selling
Entity&#8217;s audited financial statements. The recorded net sales shall be equal to gross sales minus appropriate deductions, each to the extent actually incurred, allowed, taken or paid and not otherwise recovered, which shall be booked by such
Selling Entity in accordance with Accounting Standards, such as: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) trade, quantity and cash discounts; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) rebates, chargebacks, reimbursements, fees or similar payments to wholesalers and other distributors, pharmacies and other retailers,
buying groups (including group purchasing organizations), health care insurance carriers, pharmacy benefit management companies, health maintenance organizations, Governmental Authorities, or other institutions or health care organizations,
including Medicare, Medicaid, managed healthcare and similar types of rebates; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) amounts repaid or credited by reasons of defects,
rejections, recalls or returns of Product; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) amounts provided or credited to customers through coupons and other discount programs; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) costs of freight, insurance, import/export, and other transportation charges directly related to the distribution of Product, to the extent
included in gross sales; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) that portion of the annual fee on prescription drug manufacturers imposed by the Patient Protection and
Affordable Care Act, Pub. L. <FONT STYLE="white-space:nowrap">No.&nbsp;111-148</FONT> (as amended) and reasonably allocable to sales of the Product; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) bad debts and uncollectable invoiced amounts, provided that any such amounts subsequently collected will be included in Net Sales; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) taxes, duties or other governmental charges (including any tax such as a value added or similar tax or government charge other than an
income tax, for the avoidance of doubt net of reimbursement of any value-added taxes actually received) levied on or measured by the billing amount for Product, as adjusted for rebates and refunds; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) delayed ship order credits, discounts or payments related to the impact of price increases between purchase and shipping dates; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) any other customary deductions that are consistent with Accounting Standards, but which may not be duplicative of the deductions specified
in (a) &#8211; (f) above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In no event will any particular amount identified above be deducted more than once in calculating Net Sales
(i.e., no &#8220;double counting&#8221; of reductions). Sales of Product between any Selling Entity for resale shall be excluded from the computation of Net Sales, but the subsequent resale by a Selling Entity of such Product to a third party for
end use or consumption shall be included within the computation of Net Sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary herein, disposal or use of Product
for, marketing, regulatory or development purposes, such as clinical trials, compassionate use or indigent patient programs, without direct or indirect consideration, shall not be deemed a sale for purposes of this Net Sales definition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Officer&#8217;s Certificate</U>&#8221; means a certificate signed by an authorized officer of Parent, in his or her capacity as such
an officer, and delivered to the Rights Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Out of the Money Options</U>&#8221; shall have the meaning assigned to such term
in the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Permitted Transfer</U>&#8221; means a transfer of one or more CVRs (a)&nbsp;upon death of a Holder by
will or intestacy, (b)&nbsp;by instrument to an <I>inter vivos </I>or testamentary trust in which the CVRs are passed to beneficiaries of the Holder upon the death of the Holder, (c)&nbsp;pursuant to a court order (including in connection with
bankruptcy or liquidation), (d) by operation of law (including by consolidation or merger) or without consideration in connection with the dissolution, liquidation or termination of any corporation, limited liability company, partnership or other
entity, (e)&nbsp;in the case of CVRs held in book-entry or other similar nominee form, from a nominee to a beneficial owner and, if applicable, through an intermediary, to the extent allowable by DTC, (f)&nbsp;if the Holder is a partnership or
limited liability company, a distribution by such Holder to its partners or members, as applicable (provided that such distribution does not subject the CVRs to a requirement of registration under the Securities Act of 1933 or the Securities
Exchange Act of 1934 or any securities or &#8220;blue sky&#8221; laws of any state or other jurisdiction), or (g)&nbsp;as provided in <U>Section</U><U></U><U>&nbsp;2.6</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Person</U>&#8221; means any individual, Entity or Governmental Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Product</U>&#8221; means (a)&nbsp;an Injection Product or
(b)&nbsp;FUROSCIX<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Infusor (furosemide injection) as described in NDA 209988. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Product Transfer</U>&#8221; means any sale, assignment, transfer or exclusive license of all or substantially all of the rights to
research, develop, apply for Regulatory Approval for, manufacture, commercialize and otherwise exploit the Products worldwide to a third party. For clarity, any Change of Control Transaction, any transactions with any third party service provider
(e.g., contract manufacturers) or any Incidental Contracts shall not constitute a Product Transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Regulatory
Approval</U>&#8221; means, with respect to a biopharmaceutical product, such approvals (including NDAs or any supplements thereto), licenses, registrations, or authorizations of the FDA necessary to manufacture, use, store, import, transport,
commercially distribute, sell, and market such product in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Representative</U>&#8221; shall have the meaning
assigned to such term in the Merger Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Rights Agent</U>&#8221; means the Rights Agent named in the preamble to this
Agreement, until a successor Rights Agent becomes such pursuant to the applicable provisions of this Agreement, and thereafter &#8220;Rights Agent&#8221; shall mean such successor Rights Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Selling Entity</U>&#8221; means (a)&nbsp;Parent, (b) any Assignee, (c)&nbsp;any Affiliate of Parent or any Assignee or (d)&nbsp;any
(sub)licensee of any of the foregoing in (a)&nbsp;through (c) of the rights under the Company Intellectual Property Rights owned or controlled by Company or any of its Subsidiaries as of the Effective Time and that has the right to (i)&nbsp;develop
and apply for Regulatory Approval for an Injection Product or (ii)&nbsp;commercialize a Product. &#8220;Selling Entity&#8221; excludes any (sub)contractors or distributors of any of the foregoing in (a)&nbsp;through (c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Subsidiary</U>&#8221; means, with respect to any Person (a)&nbsp;a corporation more than fifty percent (50%) of the combined voting
power of the outstanding voting stock of which is owned, directly or indirectly, by such Person or by one or more other Subsidiaries of such Person or by such Person and one or more other Subsidiaries thereof, (b)&nbsp;a partnership of which such
Person or one or more other Subsidiaries of such Person or such Person and one or more other Subsidiaries thereof, directly or indirectly, is the general partner and has the power to direct the policies, management and affairs of such partnership,
(c)&nbsp;a limited liability company of which such Person or one or more other Subsidiaries of such Person or such Person and one or more other Subsidiaries thereof, directly or indirectly, is the managing member and has the power to direct the
policies, management and affairs of such company or (d)&nbsp;any other Person (other than a corporation, partnership or limited liability company) in which such Person or one or more other Subsidiaries of such Person or such Person and one or more
other Subsidiaries thereof, directly or indirectly, has at least a majority ownership and power to direct the policies, management and affairs thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Surviving Corporation</U>&#8221; shall have the meaning assigned to such term in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Tax</U>&#8221; shall have the meaning assigned to such term in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Tax Return</U>&#8221; shall have the meaning assigned to such term in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Taxing Authority</U>&#8221; shall have the meaning assigned to such term in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Transactions</U>&#8221; shall have the meaning assigned to such term in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.2 <U>Rules</U><U> </U><U>of </U><U>Construction</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Unless otherwise indicated, all references herein to Articles, Sections, Annexes, Exhibits or Schedules, shall be deemed to refer to
Articles, Sections, Annexes, Exhibits or Schedules of or to this Agreement, as applicable, and all references herein to &#8220;paragraphs&#8221; or &#8220;clauses&#8221; shall be deemed references to separate paragraphs or clauses of the section or
subsection in which the reference occurs. The words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby,&#8221; &#8220;herewith&#8221; and words of similar import shall, unless otherwise stated, be construed to refer to this Agreement as a
whole and not to any particular provision of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Unless otherwise indicated, the words &#8220;include,&#8221; &#8220;includes&#8221; and
&#8220;including,&#8221; when used herein, shall be deemed in each case to be followed by the words &#8220;without limitation.&#8221; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
Unless otherwise indicated, all references herein to the Subsidiaries of a Person shall be deemed to include all direct and indirect Subsidiaries of such Person unless otherwise indicated or the context otherwise requires. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) If a term is defined as one part of speech (such as a noun), it shall have a corresponding meaning when used as another part of speech
(such as a verb). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine,
feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural, and vice versa. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The term
&#8220;or&#8221; is not exclusive. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) When used herein, the word &#8220;extent&#8221; and the phrase &#8220;to the extent&#8221; shall
mean the degree to which a subject or other thing extends, and such word or phrase shall not simply mean &#8220;if.&#8221; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The table
of contents and headings set forth in this Agreement are for convenience of reference purposes only and shall not affect or be deemed to affect in any way the meaning or interpretation of this Agreement or any term or provision hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) References to &#8220;$&#8221; and &#8220;dollars&#8221; are to the currency of the United States of America. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Any dollar or percentage thresholds set forth herein shall not be used as a benchmark for the determination of what is or is not
&#8220;material&#8221; under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing,
typing and other means of reproducing words (including electronic media) in a visible form. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) Except as otherwise specified,
(i)&nbsp;references to any statute or Law shall be deemed to refer to such statute or Law as amended from time to time and to any rules or regulations promulgated thereunder, (ii)&nbsp;references to any Person include the successors and permitted
assigns of that Person, and (iii)&nbsp;references from or through any date mean from and including or through and including, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) Whenever this Agreement refers to a number of days, such number shall refer to calendar days unless Business Days are specified. Whenever
any action must be taken hereunder on or by a day that is not a Business Day, then such action may be validly taken on or by the next day that is a Business Day. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) Where used with respect to information, the phrases &#8220;provided,&#8221; &#8220;delivered&#8221; or &#8220;made available&#8221; means
that the information referred to has been physically or electronically delivered to the relevant parties or their respective Representatives including, in the case of &#8220;made available&#8221; to Parent or its Affiliates or its Representatives,
material that has been posted in the &#8220;data room&#8221; (virtual or otherwise) established by the Company at least one day prior to the date hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) The parties hereto agree that they have been represented by counsel during the
negotiation and execution of this Agreement and, therefore, waive the application of any Law, holding or rule of construction providing that ambiguities in an agreement or other document will be construed against the party drafting such agreement or
document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 2 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONTINGENT VALUE RIGHTS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1 <U>CVRs; Authority; Appointment of Rights Agent</U>. The CVRs represent the rights of their respective Holders (which rights
were granted to the initial Holders pursuant to the Merger Agreement) to receive certain contingent cash payments pursuant to this Agreement. Parent has all requisite corporate power and authority to execute and deliver this Agreement and to perform
its obligations hereunder and to consummate the transactions contemplated by this Agreement. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary
corporate action on the part of the Parent and no other corporate proceedings on the part of Parent are necessary to authorize this Agreement or to consummate the transactions contemplated hereby. This Agreement has been duly executed and delivered
by Parent and, assuming the due authorization, execution and delivery by the Rights Agent, constitutes a legal, valid and binding obligation of Parent, enforceable against Parent in accordance with its terms. Neither the execution and delivery of
this Agreement nor the performance by Parent of its obligations hereunder or the consummation of the transactions contemplated hereby will (i)&nbsp;conflict with, or result in any violation of any provision of the certificate of incorporation,
bylaws and other similar organizational documents of Parent, or (ii)&nbsp;conflict with, or result in any violation of or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or
acceleration of any obligation under, any loan or credit agreement, note, mortgage, indenture, lease, or other agreement, obligation, instrument, permit, concession, franchise, license, judgment, order, decree, statute, law, ordinance, rule or
regulation applicable to Parent or its properties or assets which violation, in the case of clause (ii), individually or in the aggregate, would reasonably be expected to be material to Parent. Except as required in connection with the consummation
of the Offer and the Merger, no consent, approval, order or authorization of, or registration, declaration, notice or filing with, any Governmental Authority is required by or with respect to Parent in connection with the execution and delivery of
this Agreement by Parent or the consummation by Parent of the transactions contemplated hereby. Parent hereby appoints Broadridge Corporate Issuer Solutions, LLC as the Rights Agent to act as rights agent for Parent in accordance with the
instructions hereinafter set forth in this Agreement, and Broadridge Corporate Issuer Solutions, LLC hereby accepts such appointment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2 <U>Nontransferable</U>. The CVRs may not be sold, assigned, transferred, pledged, encumbered or in any other manner
transferred or disposed of, in whole or in part, other than through a Permitted Transfer. Any attempted sale, assignment, transfer, pledge, encumbrance or disposition of CVRs, in whole or in part, in violation of this <U>Section&nbsp;2.2</U> shall
be null and <I>void ab initio</I> and of no effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3 <U>No</U><U> </U><U>Certificate;</U><U> </U><U>Registration;</U><U>
</U><U>Registration</U><U> </U><U>of</U><U> </U><U>Transfer;</U><U> </U><U>Change</U><U> </U><U>of</U><U> Address</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The CVRs will
not be evidenced by a certificate or other instrument. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Rights Agent will keep a register (the &#8220;<U>CVR</U><U>
</U><U>Register</U>&#8221;) for the purpose of (i)&nbsp;identifying the Holders of CVRs, and (ii)&nbsp;registering CVRs and Permitted Transfers thereof. The CVR Register will initially show one position for Cede&nbsp;&amp; Co. representing all the
Company Shares held by DTC on behalf of the street holders of the Company Shares as of immediately prior to the Effective Time. The Rights Agent will have no responsibility whatsoever directly to the street name holders with respect to transfers of
CVRs unless and until such CVRs are transferred into the name of such street name holders in accordance with <U>Section</U><U></U><U>&nbsp;2.2</U>. With respect to any payments to be made under <U>Section&nbsp;2.4</U>, the Rights Agent will
accomplish the payment to any former street name holders of Company Shares by sending one lump sum payment to DTC. The Rights Agent will have no responsibilities whatsoever with regard to the distribution of payments by DTC to such street name
holders. The Rights Agent hereby acknowledges the restrictions on transfer contained in <U>Section</U><U>&nbsp;2.2</U> and agrees not to register a transfer which does not comply with <U>Section</U><U></U><U>&nbsp;2.2</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Subject to the restrictions on transferability set forth in <U>Section</U><U></U><U>&nbsp;2.2</U> and subject to the Rights Agent&#8217;s
bona fide procedures to validate the identity of a Holder, every request made to transfer a CVR must be in writing and accompanied by a written instrument of transfer in a form reasonably satisfactory to the Rights Agent pursuant to its guidelines,
duly executed by the Holder thereof, the Holder&#8217;s attorney duly authorized in writing, the Holder&#8217;s personal representative or the Holder&#8217;s survivor, and setting forth in reasonable detail the circumstances relating to the proposed
transfer. Upon receipt of such written notice and proper validation of the identity of such Holder, the Rights Agent will, subject to its reasonable determination that the transfer instrument is in proper form and the proposed transfer otherwise
complies with the other terms and conditions of this Agreement (including the provisions of <U>Section</U><U>&nbsp;2.2</U>), register the transfer of the CVRs in the CVR Register and notify Parent of the same. Parent and Rights Agent may require
payment of a sum sufficient to cover any stamp or other Tax or governmental charge that is imposed in connection with any such registration of transfer. The Rights Agent will have no duty or obligation to take any action under any Section of this
Agreement that requires the payment by a Holder of a CVR of applicable Taxes or charges unless and until the Rights Agent is satisfied that all such Taxes or charges have been paid. All duly transferred CVRs registered in the CVR Register will be
the valid obligations of Parent and will entitle the transferee to the same benefits and rights under this Agreement as those held immediately prior to the transfer by the transferor. No transfer of a CVR will be valid until registered in the CVR
Register in accordance with this Agreement, and any transfer not duly registered in the CVR Register will be void and invalid. All costs and expenses related to any transfer or assignment of the CVRs (including the cost of any transfer tax) will be
the responsibility of the transferor or assignor, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) A Holder (or an authorized representative thereof) may make a written
request to the Rights Agent to change such Holder&#8217;s address of record in the CVR Register. The written request must be duly executed by the Holder (or an authorized representative thereof). Upon receipt of such written notice and proper
validation of the identity of such Holder, the Rights Agent will promptly record the change of address in the CVR Register. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4 <U>Payment</U><U> </U><U>Procedures</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If a Milestone is achieved on or prior to the applicable Milestone Outside Date, then (i)&nbsp;as soon as reasonably practicable following
the achievement of the applicable Milestone (and in any event no later than thirty (30)&nbsp;days) after the date on which the applicable Milestone is achieved, Parent shall deliver (or cause to be delivered) to the Rights Agent a written notice
(each, a &#8220;<U>Milestone Notice</U>&#8221; and each date on which such Milestone Notice is delivered to the Rights Agent, a &#8220;<U>Milestone Notice Date</U>&#8221;) indicating which Milestone has been achieved (or indicating that both
Milestones were achieved) and (ii)&nbsp;no later than ten (10)&nbsp;Business Days after the applicable Milestone Notice Date (the &#8220;<U>Milestone Payment Date</U>&#8221;), Parent shall deliver to the Rights Agent cash, by wire transfer of
immediately available funds to an account specified by the Rights Agent, equal to the aggregate amount necessary to pay the applicable Milestone Payment Amount to all Holders other than Equity Award Holders with respect to which the applicable
Milestone Payment Amount is subject to deduction for any required withholding Tax (&#8220;<U>Employee</U> <U>Equity Award Holders</U>&#8221;) (with respect to which any such amounts payable shall be retained by Parent for payment pursuant to
<U>Section</U><U></U><U>&nbsp;2.4(b)</U> of this Agreement and Section&nbsp;3.5 of the Merger Agreement). The Milestone Payment Amount with respect to Milestone 1 shall only be paid in respect of Milestone 1, if at all, one time under this
Agreement, and the Milestone Payment Amount with respect to Milestone 2 shall only be paid in respect of Milestone 2, if at all, one time under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Rights Agent shall promptly, and in any event within ten (10)&nbsp;Business Days of receipt of a Milestone Notice, send each Holder
(other than Employee Equity Award Holders) at its registered address a copy of the applicable Milestone Notice and pay, subject to deduction for any required withholding Tax pursuant to Section&nbsp;3.7 of the Merger Agreement, the applicable
Milestone Payment Amount to each such Holder by check mailed to the address of each such Holder as reflected in the CVR Register as of 5:00 p.m., Eastern time, on the date of the applicable Milestone Notice. Parent (i)&nbsp;shall promptly, and in
any event within ten (10)&nbsp;Business Days after delivery to the Rights Agent of the applicable Milestone Notice, send each Employee Equity Award Holder at such Employee Equity Award Holder&#8217;s registered address a copy of such Milestone
Notice and (ii)&nbsp;with respect to any portion of the applicable Milestone Payment that is payable to each such Employee Equity Award Holder, shall, as soon as reasonably practicable following the applicable Milestone Payment Date (but in any
event no later than the next regularly scheduled payroll date that is at least five (5)&nbsp;Business Days following such Milestone Payment Date, and in all events no later than the date that is seventy-five (75)&nbsp;days following the date on
which the applicable Milestone is achieved), pay, or shall cause the Surviving Corporation or an Affiliate thereof to pay through Parent&#8217;s, the Company&#8217;s or such Affiliate&#8217;s payroll system or accounts payable systems, as applicable
(and subject to deduction for any required withholding Tax pursuant to Section&nbsp;3.7 of the Merger Agreement), the applicable Milestone Payment Amount payable to each such Employee Equity Award Holder in accordance with Section&nbsp;3.6 of the
Merger Agreement. Notwithstanding anything in this Agreement to the contrary, it is the intent of the parties that the Milestones shall be deemed a conditional payment that constitutes a substantial risk of forfeiture within the meaning of
Section&nbsp;409A of the Code and that any Milestone Payment Amounts with respect to Company Stock Awards be exempt from Section&nbsp;409A of the Code. For purposes of Section&nbsp;409A of the Code, each payment in respect of a Company Stock Award
under Section&nbsp;3.6 of the Merger Agreement or this Agreement shall be treated as a separate payment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Unless otherwise required as a result of a change of law, and except to the extent any
portion of the Milestone Payment is required to be treated as imputed interest pursuant to applicable Tax Law, the parties hereto agree to treat the CVRs for all U.S. federal and applicable state and local income Tax purposes as additional
consideration paid at the Effective Time for the Company Shares (or, to the extent the CVRs are received with respect to In the Money Options or Company RSU Awards, as wages or other compensation for services in the year in which the applicable
Milestone Payment Amount is made) pursuant to the Offer or the Merger Agreement, as the case may be, and none of the parties hereto shall take any position to the contrary on any Tax Return or for other U.S. federal and applicable state and local
income Tax purposes except as required by applicable Tax Law. Parent and the Company may report imputed interest on the CVRs (other than CVRs in respect of In the Money Options or Company RSU Awards) as required by applicable Tax Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Parent, its applicable Affiliates (including the Surviving Corporation) or any other applicable withholding agent shall be entitled to
deduct and withhold, or cause the Rights Agent to deduct and withhold, from any Milestone Payment Amount or any other amounts otherwise payable pursuant to this Agreement such amounts as may be required to be deducted and withheld therefrom under
applicable Tax Law, as may reasonably be determined by Parent or the Rights Agent. With respect to any amounts payable to Employee Equity Award Holders, any such Tax withholdings may be made, or caused to be made, by Parent through Parent&#8217;s,
the Surviving Corporation&#8217;s or its applicable Affiliate&#8217;s payroll system. Prior to making any such Tax deductions or withholdings or causing any such Tax deductions or withholdings to be made with respect to any Holder (other than an
Employee Equity Award Holder), Parent shall instruct the Rights Agent to solicit IRS Forms <FONT STYLE="white-space:nowrap">W-9</FONT> or <FONT STYLE="white-space:nowrap">W-8,</FONT> as applicable, or any other appropriate forms or information, from
such Holders within a reasonable amount of time in order to provide a reasonable opportunity for such Holder to avoid or reduce such withholding, and the Milestone Payment Amount may be reasonably delayed in order to gather such necessary Tax forms.
Parent, its Subsidiaries (including the Surviving Corporation) and the Rights Agent may assume all such forms in their possession or provided by any such Holder are valid under applicable Tax Law until subsequently notified by such Holder. Parent or
its applicable Subsidiary (including the Surviving Corporation) shall, or shall cause the Rights Agent to, take all action that may be necessary to ensure that any amounts deducted or withheld in respect of Taxes are promptly and properly remitted
to the appropriate Taxing Authority. To the extent any amounts are so deducted and withheld, such amounts shall be treated for all purposes of this Agreement as having been paid to the Person in respect of whom such deduction and withholding was
made, and as required by applicable Tax Law. Parent shall direct and instruct the Rights Agent regarding the Tax information reporting with respect to any Milestone Payment Amount under applicable Tax Law, and the Rights Agent will comply with any
Tax reporting obligations in accordance with applicable Tax Law and Parent&#8217;s instructions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Any portion of any aggregate
Milestone Payment Amount delivered to the Rights Agent that remains undistributed to a Holder twelve (12)&nbsp;months after the date of the delivery of the applicable Milestone Notice shall be delivered by the Rights Agent to Parent, upon demand,
and any Holder shall thereafter look only to Parent (subject to abandoned property, escheat and other similar applicable Law) for payment of such Milestone Payment Amount, without interest, but such Holder shall have no greater rights against Parent
than those accorded to general unsecured creditors of Parent under applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Neither Parent nor the Rights Agent shall be liable to any Person in respect of any
Milestone Payment Amount delivered to a public official pursuant to any applicable abandoned property, escheat or similar Law. Parent accepts all liability for any amounts owed to Holders that have been delivered to Parent in accordance with
<U>Section&nbsp;2.4(e)</U>. If, despite Parent&#8217;s and the Rights Agent&#8217;s commercially reasonable efforts to deliver a Milestone Payment Amount to the applicable Holder, such Milestone Payment Amount has not been paid prior to the date on
which such Milestone Payment Amount would otherwise escheat to any Governmental Authority, any such Milestone Payment Amount shall, to the extent permitted by applicable Law, immediately prior to such time, become the property of Parent, free and
clear of all claims or interest of any Person previously entitled thereto. In addition to and not in limitation of any other indemnity obligation herein, Parent agrees to indemnify and hold harmless the Rights Agent with respect to any liability,
penalty, cost or expense Rights Agent may incur or be subject to in connection with transferring such property to Parent. The Rights Agent will not be responsible for escheatment of abandoned property except in the case that Parent is unable to
provide the Rights Agent with the applicable wire instructions to transfer such property to Parent before the applicable Milestone Payment Amount(s) would escheat to the Governmental Authority. In such case, the Rights Agent will be required to
escheat the funds to the Governmental Authority immediately. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) All funds received by the Rights Agent under this Agreement that are to
be distributed or applied by the Rights Agent in the performance of services hereunder (the &#8220;<U>Funds</U>&#8221;) shall be held by the Rights Agent as agent for Parent and deposited in one or more bank accounts to be maintained by the Rights
Agent in its name as agent for Parent. With respect to cash deposited by the Parent with the bank or financial institution designated by the Rights Agent (currently Wells Fargo or US Bank), the Rights Agent agrees to cause such bank or financial
institution to establish and maintain a segregated <FONT STYLE="white-space:nowrap">non-interest-bearing</FONT> demand deposit subaccount therefor in the name of the Rights Agent for the benefit of Parent. The Rights Agent will only draw upon cash
in such account(s) as required from time to time in order to make payments of the Milestone Payment Amounts and any applicable tax withholding payments in accordance with this Agreement. The Rights Agent shall have no responsibility or liability for
any diminution of funds that may result from any deposit made by the Rights Agent in accordance with this paragraph, including any losses resulting from a default by any bank, financial institution or other third party, in the absence of fraud, bad
faith, gross negligence or willful misconduct by or on behalf of the Rights Agent. The Rights Agent may from time to time receive interest in connection with such deposits. The Rights Agent shall not be obligated to pay such interest to Parent, any
Holder or any other Person. The Rights Agent is acting as an agent hereunder and is not a debtor of Parent in respect of cash deposited hereunder. For the avoidance of doubt, Parent acknowledges that: (i)&nbsp;the Rights Agent is not a bank or trust
company; (ii)&nbsp;the Rights Agent is not acting in any sort of capacity as an &#8220;escrow&#8221; or similar agent hereunder; and (iii)&nbsp;nothing in this Agreement shall be construed as requiring the Rights Agent to perform any services that
would require registration with any governmental authority as a bank or trust company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The Rights Agent makes no representations or
warranties with respect to tax treatment of the CVRs. None of the Rights Agent, its Affiliates or the services provided by the Rights Agent hereunder are intended to provide legal, tax or financial advice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.5 <U>No</U><U> </U><U>Voting,</U><U> </U><U>Dividends</U><U> </U><U>or</U><U>
</U><U>Interest;</U><U> </U><U>No</U><U> </U><U>Equity</U><U> </U><U>or</U><U> </U><U>Ownership</U><U> </U><U>Interest</U><U> </U><U>in</U><U> </U><U>Parent</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The CVRs shall not have any voting or dividend rights, and interest shall not accrue on any amounts payable on the CVRs to any Holder.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The CVRs shall not represent any equity or ownership interest in Parent, any constituent company to the Merger or any of their
respective Affiliates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Neither Parent, its Affiliates nor any of their respective directors and officers will be deemed to have any
fiduciary or similar duties to any Holder by virtue of this Agreement or the CVRs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.6 <U>Ability to Abandon CVR</U>. A
Holder may at any time, at such Holder&#8217;s option, abandon all of such Holder&#8217;s remaining rights in a CVR by transferring such CVR to Parent without consideration therefor, which a Holder may effect via delivery of a written notice of such
abandonment to Parent. Nothing in this Agreement shall prohibit Parent or any of its Affiliates from offering to acquire or acquiring any CVRs for consideration from any Holder, in private transactions or otherwise, in its sole discretion. Any CVRs
acquired by Parent or any of its Affiliates shall be automatically deemed extinguished and no longer outstanding for purposes of the definition of Acting Holders and <U>Article</U><U> </U><U>5</U> and Section<U></U><U>&nbsp;6.3</U>. The Rights Agent
shall update the CVR Register to reflect any abandonment or acquisition of CVRs described in this <U>Section&nbsp;2.6</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 3 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">THE RIGHTS AGENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.1 <U>Certain</U><U> </U><U>Duties</U><U> </U><U>and</U><U> </U><U>Responsibilities</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Rights Agent shall not have any liability for any actions taken or not taken in connection with this Agreement, except to the extent
of its willful or intentional misconduct, fraud, bad faith or gross negligence (in each case as determined by a court of competent jurisdiction). In no event will the Rights Agent be liable for any special, indirect, incidental, punitive or
consequential damages arising out of or related to this Agreement (including lost profits, damage to reputation or lost savings), even if foreseeable and even if the Rights Agent has been advised of the possibility of such damages. The provisions of
this Article 3 shall survive the termination of this Agreement, the exercise or expiration of the rights of the Rights Agent, and the resignation, replacement or removal of the Rights Agent, and the exercise, termination and expiration of the CVRs.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each Holder shall be deemed to have irrevocably appointed, authorized and directed the Rights Agent (including any successor in
accordance with this <U>Article 3</U>) to act as the Rights Agent and such Holder&#8217;s agent, representative, proxy and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for the purpose of enforcing
such Holder&#8217;s rights under this Agreement, and exercising, on behalf of all Holders, the rights and powers of the Holders hereunder and thereunder. Without limiting the generality of the foregoing, the Rights Agent shall have full power and
authority, and is hereby directed, for and on behalf of the Holders, to take such action, and to exercise such rights, power and authority, as are authorized, delegated and granted to the Rights Agent hereunder in connection with the transactions
contemplated hereby or to the extent directed to by the Acting Holders in writing. Parent and its Affiliates shall be entitled to rely solely on the Rights Agent as an authorized representative of the Holders with respect to any such matters
concerning the Holders arising hereunder for which the Rights Agent is acting at the written direction of the Acting Holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Rights Agent may in its discretion or upon the written request of the Acting Holders
proceed to and shall be entitled and empowered to protect and enforce the rights of the Holders hereunder by such appropriate judicial proceedings as the Rights Agent shall deem most effectual to protect and enforce any such rights. The Rights Agent
may only proceed to and shall be entitled and empowered to protect and enforce the rights herein for the benefit of and on behalf of all Holders to the extent directed to by the Acting Holders in writing; <U>provided</U> that the Rights Agent shall
have the right to decline to follow any such direction if the Rights Agent, being advised by counsel in writing, shall determine that the action or proceeding so directed may not lawfully be taken or if the Rights Agent in good faith shall determine
that the action or proceedings so directed would involve the Rights Agent in personal liability or if the Rights Agent in good faith shall so determine that the actions or forbearances specified in or pursuant to such direction would be unduly
prejudicial to the interests of Holders not joining in the giving of said direction. No individual Holder shall be entitled to protect and enforce its rights or the rights of the Holders other than through the Rights Agent under the direction of the
Acting Holders, as provided for in this <U>Section</U><U></U><U>&nbsp;3.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.2 <U>Certain Rights of Rights Agent</U>.
The Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and no implied covenants or obligations shall be read into this Agreement against the Rights Agent. In addition: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the Rights Agent may rely upon and shall be protected and held harmless by Parent in acting or refraining from acting upon any resolution,
certificate, statement, instrument, opinion, report, notice, request, power of attorney, endorsement, direction, consent, order or other paper or document reasonably believed by the Rights Agent to be genuine and to have been signed, executed and,
where necessary, verified or acknowledged or presented by the proper party or parties; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) the Rights Agent may rely on and shall be held
harmless in acting upon written (including electronically transmitted) instructions from Parent or any Holder delivered to the Rights Agent in accordance with the terms of this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) whenever the Rights Agent deems it desirable that a matter be proved or established prior to taking, suffering or omitting any action
hereunder, the Rights Agent may rely upon an Officer&#8217;s Certificate, which shall constitute full authorization and protection to the Rights Agent, and the Rights Agent shall, unless such liability has been determined by a court of competent
jurisdiction to be a result of the Rights Agent&#8217;s bad faith, gross negligence, fraud or willful or intentional misconduct on its part, incur no liability and be held harmless by Parent for or in respect of any action taken, suffered or omitted
to be taken by the Rights Agent under the provisions of this Agreement in reliance upon such Officer&#8217;s Certificate; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) the Rights
Agent may engage and consult with counsel of its selection and the written advice of such counsel or any written opinion of such counsel shall be full and complete authorization and protection to the Rights Agent and the Rights Agent shall be held
harmless by Parent in respect of any action taken, suffered or omitted by the Rights Agent hereunder in good faith and in reliance thereon and that does not constitute gross negligence or willful or intentional misconduct or fraud; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) the permissive rights of the Rights Agent to do things enumerated in this Agreement
shall not be construed as a duty; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) the Rights Agent shall not be required to give any note or surety in respect of the execution of
such powers or otherwise in respect of the premises; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) the Rights Agent shall not be liable for or by reason of, and shall be held
harmless by Parent with respect to, any of the statements of fact or recitals contained in this Agreement or be required to verify the same, but all such statements and recitals are and shall be deemed to have been made by Parent only; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) the Rights Agent shall have no liability and shall be held harmless by Parent in respect of the validity of this Agreement or the execution
and delivery hereof (except the due execution and delivery hereof by the Rights Agent and the enforceability of this Agreement against the Rights Agent, assuming the due execution and delivery hereof by Parent); nor shall the Rights Agent be
responsible for any breach by Parent of any covenant or condition contained in this Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Parent shall indemnify the Rights Agent
and its affiliates, and its and their respective employees, officers, directors, representatives and advisors for, and hold such Persons harmless against, any loss, liability, claim, demand, suit or expense (including, without limitation, the
reasonable and documented fees and expenses of outside legal counsel and reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses arising directly or indirectly from
the Rights Agent enforcing its rights hereunder) arising out of or in connection with the performance of the Rights Agent&#8217;s duties under this Agreement, including the reasonable and documented <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-</FONT></FONT> pocket costs and expenses of defending the Rights Agent against any claims, charges, demands, suits or loss, unless such loss has been determined by a court of competent jurisdiction to be a result of
Rights Agent&#8217;s gross negligence, bad faith, fraud or willful or intentional misconduct; <U>provided</U> that Parent shall not be required to indemnify or hold harmless the Rights Agent in connection with any proceeding commenced by the Rights
Agent on behalf of itself or any of the Holders against Parent; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Parent shall (i)&nbsp;pay the Rights Agent the fees set forth in a
mutually executed document (the &#8220;<U>Rights Agent Fees</U>&#8221;), (ii) pay the reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-</FONT></FONT> pocket fees and expenses paid or incurred by the
Rights Agent in connection with this Agreement as agreed upon in writing by the Rights Agent and Parent on or prior to the date hereof, and (iii)&nbsp;reimburse the Rights Agent for all Taxes and governmental charges, reasonable and documented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by the Rights Agent in the execution of this Agreement (excluding, for the avoidance of doubt, Taxes imposed on or measured by the Rights
Agent&#8217;s income and any business profits, franchise or similar Taxes imposed on it in lieu of income Taxes), and for all necessary, reasonable and documented
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses paid or incurred by it in connection with the administration by the Rights Agent of its duties hereunder; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) no provision of this Agreement shall require the Rights Agent to expend or risk its own
funds or otherwise incur any financial liability in the performance of any of its duties hereunder or in the exercise of its rights if there shall be reasonable grounds for believing that repayment of such funds or adequate indemnification against
such risk or liability is not reasonably assured to the Rights Agent; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) no Holder shall be obligated to indemnify the Rights Agent for,
or hold the Rights Agent harmless against, any loss, liability, claim, demand, suit or expense arising out of or in connection with the Rights Agent&#8217;s duties under this Agreement or to pay or reimburse the Rights Agent for any fees, costs or
expenses incurred by the Rights Agent in connection with this Agreement or the administration of its duties hereunder, and the Rights Agent shall not be entitled to deduct any amount from any Milestone Payment Amount in any circumstance except as
provided in <U>Section</U><U>&nbsp;2.4(d)</U>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) the Rights Agent shall not be required to perform any action if such action would cause
the Rights Agent to violate any applicable law, regulation or court order; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) the Rights Agent shall not be deemed to have any knowledge
of any event of which it was to receive notice thereof hereunder, and the Rights Agent shall be fully protected and shall incur no liability for failing to take any action in connection therewith, unless and until it has received such notice in
writing; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) the Rights Agent shall not assume any obligations or relationship of agency or trust with any Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.3 <U>Resignation</U><U> </U><U>and</U><U> </U><U>Removal;</U><U> </U><U>Appointment</U><U> </U><U>of</U><U>
</U><U>Successor</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Rights Agent may resign at any time by giving written notice thereof to Parent specifying a date when such
resignation will take effect, which notice shall be sent at least sixty (60)&nbsp;days prior to the date so specified but in no event shall such resignation become effective until a successor Rights Agent has been appointed. Parent has the right to
remove the Rights Agent at any time by specifying a date when such removal shall take effect but no such removal shall become effective until a successor Rights Agent has been appointed. Notice of such removal shall be given by Parent to the Rights
Agent, which notice shall be sent at least sixty (60)&nbsp;days prior to the date so specified. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the Rights Agent provides notice of
its intent to resign, is removed pursuant to <U>Section&nbsp;3.3(a)</U> or becomes incapable of acting, Parent shall as soon as is reasonably possible appoint a qualified successor Rights Agent who has been approved in writing by the Acting Holders,
which successor shall be a stock transfer agent of national reputation or the corporate trust department of a commercial bank. The successor Rights Agent so appointed shall, forthwith upon its acceptance of such appointment in accordance with
Section<U></U><U>&nbsp;3.4</U>, become the successor Rights Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Parent shall give or cause to be given notice of each resignation
and each removal of a Rights Agent and each appointment of a successor Rights Agent by mailing written notice of such event by first-class mail to the Holders as their names and addresses appear in the CVR Register. Each notice shall include the
name and address of the successor Rights Agent. If Parent fails to send or cause to be sent such notice within ten (10)&nbsp;days after acceptance of appointment by a successor Rights Agent in accordance with <U>Section&nbsp;3.4</U>, the successor
Rights Agent shall cause the notice to be mailed at the expense of Parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) As long as all fees and charges that are due and payable to the Rights Agent for the
Right&#8217;s Agent&#8217;s service performed under this Agreement have been paid, the Rights Agent shall cooperate with Parent and any successor Rights Agent as reasonably requested in connection with the transition of the duties and
responsibilities of the Rights Agent to the successor Rights Agent, including transferring the CVR Register to the successor Rights Agent. The Rights Agent shall be entitled to reimbursement by Parent for reasonable and documented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses related to such transition services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.4 <U>Acceptance of Appointment by Successor</U>. Every successor Rights Agent appointed pursuant to
<U>Section</U><U></U><U>&nbsp;3.3(b)</U> shall execute, acknowledge and deliver to Parent and to the retiring Rights Agent an instrument accepting such appointment and a counterpart of this Agreement, and thereupon such successor Rights Agent,
without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties of the retiring Rights Agent. On request of Parent or the successor Rights Agent, the retiring Rights Agent shall execute and deliver an
instrument transferring to the successor Rights Agent all the rights, powers and trusts of the retiring Rights Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 4 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COVENANTS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1
<U>List of Holders</U>. Parent shall furnish or cause to be furnished to the Rights Agent (a)&nbsp;in such form as Parent receives from the Company&#8217;s transfer agent (or other agent performing similar services for the Company with respect to
the Company Shares), the names and addresses of the Holders of such securities within thirty (30)&nbsp;Business Days after the Effective Time and (b)&nbsp;in the case of Employee Equity Award Holders, the names and addresses of the Holders of such
securities set forth in the books and records of the Company at the Effective Time and in accordance with the terms of the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2 <U>Books</U><U> </U><U>and</U><U> </U><U>Records</U>. Parent shall, and shall cause its controlled Affiliates to, keep
records in sufficient detail to enable the Holders to determine the amounts payable hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3 <U>Additional</U><U>
</U><U>Covenants</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) With respect to each Milestone, from the Effective Time until the earlier of </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) the date on which such Milestone has been achieved and (ii)&nbsp;the Milestone Outside Date for such Milestone, Parent shall, directly or through any
applicable Selling Entity, use Commercially Reasonable Efforts to achieve such Milestone. For the avoidance of doubt, Parent does not guarantee (and the use of any &#8220;Commercially Reasonable Efforts&#8221; hereunder does not mean nor shall it be
deemed or interpreted to mean) that any Milestone will be achieved by a specific date or at all, and a failure to achieve a Milestone may nonetheless be consistent with the use of &#8220;Commercially Reasonable Efforts&#8221;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If Parent consummates a Product Transfer to a third party that is not an Affiliate of
Parent while either Milestone has not been achieved prior to the applicable Milestone Outside Date, then (i)&nbsp;Parent shall provide notice to the Rights Agent of the consummation of such Product Transfer no more than five (5)&nbsp;Business Days
after the consummation thereof, which notice shall specify the date on which such Product Transfer was consummated; (ii)&nbsp;any Milestone that has not yet been achieved shall be deemed to have been attained and shall be paid in accordance with
<U>Section</U><U></U><U>&nbsp;2.4(a)</U> as if such Milestone(s) had been attained prior to the Milestone Outside Date; and (iii)&nbsp;Parent shall pay the Milestone Payment to the Rights Agent on the date of notice of such consummation of such
Product Transfer, in accordance with <U>Section</U><U></U><U>&nbsp;2.4(a)</U> as if such Milestone had been attained prior to the Milestone Outside Date; <I>provided </I>that for purposes of the foregoing clauses (ii)&nbsp;and (iii), (A) if
Milestone 1 has not yet been achieved prior to the consummation of such Product Transfer, and the Product Transfer is consummated (1)&nbsp;on or prior to September&nbsp;30, 2026, the Milestone 1 Milestone Payment shall be $0.625 without interest,
(2)&nbsp;between October 1, 2026 and December 31, 2026, the Milestone 1 Milestone Payment shall be $0.375 without interest, (3)&nbsp;between January 1, 2027 and June 30, 2027, the Milestone 1 Milestone Payment shall be $0.25 without interest, and
(4)&nbsp;on or after July 1, 2027, the Milestone 1 Payment shall be $0; and (B)&nbsp;if Milestone 2 has not yet been achieved prior to the consummation of such Product Transfer, the Milestone 2 Milestone Payment shall be (1) $0.175 on or prior to
December&nbsp;31, 2026 and (2) $0 on or after January 1, 2027. Upon the payment in full of any such amount, all of the CVRs then outstanding and this Agreement shall thereupon automatically terminate and become null and void without any further
action on the part of any party hereto, and the holders thereof and the parties hereto shall have no further rights with respect thereto or hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 5 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDMENTS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.1 <U>Amendments</U><U> </U><U>without</U><U> </U><U>Consent</U><U> </U><U>of</U><U> </U><U>Holders</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Without the consent of any Holders, Parent, at any time and from time to time, may enter into one or more amendments hereto, for any of the
following purposes: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) to evidence the succession of another Person to Parent and the assumption by any such successor of the covenants
of Parent herein as provided in <U>Section&nbsp;6.3</U>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) to add to the covenants of Parent such further covenants, restrictions,
conditions or provisions as Parent and the Rights Agent will consider to be for the protection or benefit of the Holders; <U>provided</U> that, in each case, such provisions do not adversely affect the interests of the Holders; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) to cure any ambiguity, to correct or supplement any provision herein that may be defective or inconsistent with any other provision
herein, or to make any other provisions with respect to matters or questions arising under this Agreement; <U>provided</U> that, in each case, such provisions do not adversely affect the interests of the Holders; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) as may be necessary or appropriate to ensure that the CVRs are not subject to registration under the Securities Act of 1933, the
Securities Exchange Act of 1934 or any applicable state securities or &#8220;blue sky&#8221; Laws; <U>provided</U>, that, in each case, such provisions do not adversely affect the interests of the Holders; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) to evidence the succession of another Person as a successor Rights Agent and the
assumption by any such successor of the covenants and obligations of the Rights Agent herein in accordance with Section<U></U><U>&nbsp;3.3</U> and <U>Section</U><U></U>&nbsp;3.4; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) to evidence the assignment of this Agreement by Parent as provided in <U>Section&nbsp;6.3</U>; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) any other amendments hereto for the purpose of adding, eliminating or changing any provisions of this Agreement, unless such addition,
elimination or change is adverse to the interests of the Holders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Without the consent of any Holders, Parent and the Rights Agent, at
any time and from time to time, may enter into one or more amendments hereto, to reduce the number of CVRs, in the event any Holder agrees to renounce such Holder&#8217;s rights under this Agreement in accordance with
<U>Section</U><U></U><U>&nbsp;2.6</U> or <U>Section</U><U></U><U>&nbsp;6.4</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Promptly after the execution and delivery by Parent
and the Rights Agent of any amendment pursuant to the provisions of this <U>Section&nbsp;5.1</U>, Parent shall mail (or cause the Rights Agent to mail at Parent&#8217;s sole cost and expense) a notice thereof through the facilities of DTC in
accordance with DTC&#8217;s procedures or by first class mail to the Holders at their addresses as they appear on the CVR Register, setting forth such amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2 <U>Amendments</U><U> </U><U>with</U><U> </U><U>Consent</U><U> </U><U>of</U><U> </U><U>Holders</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to <U>Section</U><U></U><U>&nbsp;5.1</U> (which amendments pursuant to <U>Section&nbsp;5.1</U> may be made without the consent of
the Holders), with the consent of the Acting Holders, whether evidenced in writing or taken at a meeting of the Holders, Parent and the Rights Agent may enter into one or more amendments hereto for the purpose of adding, eliminating or changing any
provisions of this Agreement, even if such addition, elimination or change is materially adverse to the interest of the Holders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
Promptly after the execution and delivery by Parent and the Rights Agent of any amendment pursuant to the provisions of this <U>Section&nbsp;5.2</U>, Parent shall mail (or cause the Rights Agent to mail at Parent&#8217;s sole cost and expense) a
notice thereof through the facilities of DTC in accordance with DTC&#8217;s procedures or by first class mail to the Holders at their addresses as they appear on the CVR Register, setting forth such amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3 <U>Execution of Amendments</U>. In executing any amendment permitted by this <U>Article 5</U>, the Rights Agent shall be
entitled to receive, and shall be fully protected in relying upon, an opinion of counsel selected by Parent stating that the execution of such amendment is authorized or permitted by this Agreement. The Rights Agent may, but is not obligated to,
enter into any such amendment that it reasonably determines adversely affects the Rights Agent&#8217;s own rights, privileges, covenants or duties under this Agreement or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.4 <U>Effect of Amendments</U>. Upon the execution of any amendment under this <U>Article 5</U>, this Agreement shall be
modified in accordance therewith, such amendment shall form a part of this Agreement for all purposes and every Holder shall be bound thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 6 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OTHER PROVISIONS OF GENERAL APPLICATION </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.1 <U>Notices to Rights Agent and Parent</U>. All notices, requests and other communications to any party hereunder shall be in
writing (including electronic mail <FONT STYLE="white-space:nowrap">(&#8220;e-mail&#8221;)</FONT> transmission, so long as a receipt of such <FONT STYLE="white-space:nowrap">e-mail</FONT> is requested and received or otherwise with acknowledgement
of receipt) and shall be given: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">if to the Rights Agent, to it at: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Broadridge Corporate Issuer Solutions, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">51 Mercedes Way </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Edgewood, New
York 11717 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: BCIS IWS </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: legalnotices@broadridge.com; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">BCISCAManagement@broadridge.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">With a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Broadridge Financial Solutions, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">2 Gateway Center </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Newark, New
Jersey 07102 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: legalnotices@broadridge.com; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><U>BCISCAManagement@broadridge.com</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">if to Parent, to it at: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">MannKind Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">30930
Russell Ranch Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Suite 300 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Westlake Village, CA 91362 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> legal@mannkindcorp.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">10265 Science
Center Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Barbara Borden; Rowook Park </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> bborden@cooley.com; rpark@cooley.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address, facsimile number or <FONT STYLE="white-space:nowrap">e-mail</FONT> address as such party may hereafter specify for the purpose by
notice to the other parties hereto pursuant to this <U>Section</U><U></U><U>&nbsp;6.1</U>. All such notices, requests and other communications shall be duly delivered and received hereunder: (a)&nbsp;four Business Days after being sent by registered
or certified mail, return receipt requested, postage </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">prepaid; (b)&nbsp;one Business Day after being sent for next Business Day delivery, fees prepaid, via a
reputable nationwide overnight courier service; (c)&nbsp;if sent by email transmission prior to 6:00 p.m. recipient&#8217;s local time, upon transmission (provided that the sender of such email does not receive written notification of delivery
failure); or (d)&nbsp;if sent by email transmission after 6:00 p.m. recipient&#8217;s local time, the Business Day following the date of transmission (provided that the sender of such email does not receive written notification of delivery failure).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.2 <U>Notice to Holders</U>. Where this Agreement provides for notice to Holders, such notice shall be sufficiently given
(unless otherwise herein expressly provided) if in writing and transmitted through the facilities of DTC in accordance with DTC&#8217;s procedures or mailed, first-class postage prepaid, to each Holder affected by such event, at the Holder&#8217;s
address as it appears in the CVR Register, not later than the latest date, and not earlier than the earliest date, if any, prescribed for the giving of such notice. In any case where notice to Holders is given by mail, neither the failure to mail
such notice, nor any defect in any notice so mailed, to any particular Holder shall affect the sufficiency of such notice with respect to other Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.3 <U>Parent Successors and Assigns</U>. Parent may assign any or all of its rights, interests and obligations hereunder
(a)&nbsp;in its sole discretion and without the consent of any other party to (i)&nbsp;any Affiliate of Parent, but only for so long as it remains an Affiliate of Parent, (ii)&nbsp;any third party in accordance with
<U>Section</U><U></U><U>&nbsp;4.3(b)</U> or (iii)&nbsp;in connection with a Change of Control Transaction or (b)&nbsp;with the prior written consent of the Acting Holders to any other Person (any permitted assignee under clause (a)&nbsp;or (b), an
&#8220;<U>Assignee</U>&#8221;), in each case provided that the Assignee agrees, in an instrument supplemental hereto, executed and delivered to the Rights Agent, to assume and be bound by all of the terms of this Agreement. Any Assignee may
thereafter assign any or all of its rights, interests and obligations hereunder in the same manner as Parent pursuant to the prior sentence. In connection with any assignment to an Assignee described in clause (a)(i) above in this
<U>Section</U><U></U><U>&nbsp;6.3</U>, Parent (or the other applicable assignor) shall agree to remain liable for the performance by each Assignee (and such other assignor, if applicable) of all obligations of Parent hereunder, including the due and
punctual payment of the CVRs and the due and punctual performance and observation of all of the covenants and obligations of this Agreement to be performed or observed by Parent, with such Assignee substituted for Parent under this Agreement. This
Agreement shall be binding upon, inure to the benefit of and be enforceable by Parent&#8217;s successors and each Assignee. The Rights Agent may not assign this Agreement without Parent&#8217;s prior written consent. Any attempted assignment of this
Agreement or any such rights in violation of this <U>Section</U><U></U><U>&nbsp;6.3</U> shall be void and of no effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.4
<U>Benefits</U><U> </U><U>of</U><U> </U><U>Agreement</U>. Nothing in this Agreement, express or implied, shall give to any Person (other than the Rights Agent, Parent, Parent&#8217;s successors and Assignees, the Holders and the Holders&#8217;
successors and assigns permitted pursuant to a Permitted Transfer) any benefit or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision herein contained, all such covenants and provisions being for the
sole benefit of the foregoing. The rights of Holders and their successors and assigns pursuant to Permitted Transfers are limited to those expressly provided in this Agreement and the Merger Agreement. Notwithstanding anything to the contrary
contained herein, any Holder or Holder&#8217;s successor or assign pursuant to a Permitted Transfer may agree to renounce, in whole or in part, its rights under this Agreement by written notice to the Rights Agent and Parent, which notice, if given,
shall be irrevocable. Notwithstanding anything to the contrary contained herein, except for the rights of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rights Agent expressly set forth herein, the Acting Holders shall have the sole right, on behalf of all
Holders, by virtue of or under any provision of this Agreement or otherwise, to institute any action or proceeding with respect to this Agreement, and no individual Holder or other group of Holders shall be entitled to exercise any rights under any
provision of this Agreement or otherwise (provided that the foregoing shall not limit the ability of an individual Holder to seek a payment due from the applicable party pursuant to <U>Section</U><U></U><U>&nbsp;2.4</U> solely to the extent that
such payment has been finally determined to be due and payable under this Agreement and has not been paid when due). All Holders (including the Acting Holders) must enforce any such legal or equitable rights, remedies or claims under this Agreement
against Parent and not against the Rights Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.5 <U>Governing</U><U> </U><U>Law;</U><U> </U><U>Jurisdiction;</U><U>
</U><U>WAIVER</U><U> </U><U>OF</U><U> </U><U>JURY</U><U> </U><U>TRIAL</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) This Agreement, the CVRs and all actions arising under or
in connection therewith shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction)
that would cause the application of laws of any jurisdiction other than those of the State of Delaware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The parties hereto agree that
any action, litigation or suit seeking to enforce any provision of, or based on any matter arising out of or in connection with, this Agreement or the transactions contemplated hereby (whether brought by any party hereto or any of its Affiliates or
against any party hereto or any of its Affiliates) shall be brought in the Delaware Chancery Court or, if such court shall not have jurisdiction, any federal court located in the State of Delaware or other Delaware state court, and each of the
parties hereto hereby irrevocably consents to the exclusive jurisdiction of such courts (and of the appropriate appellate courts therefrom) in any such action, litigation or suit and irrevocably waives, to the fullest extent permitted by Law, any
objection that it may now or hereafter have to the laying of the venue of any such action, litigation or suit in any such court or that any such action, litigation or suit brought in any such court has been brought in an inconvenient forum. Process
in any such action, litigation or suit may be served on any party hereto anywhere in the world, whether within or without the jurisdiction of any such court. Without limiting the foregoing, each party hereto agrees that service of process on such
party as provided in <U>Section</U><U></U><U>&nbsp;6.1</U> shall be deemed effective service of process on such party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) EACH OF THE
PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE TRANSACTIONS
CONTEMPLATED HEREBY OR THE ACTIONS OF ANY OF THE PARTIES HERETO IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF. EACH PARTY HERETO CERTIFIES AND ACKNOWLEDGES THAT (A)&nbsp;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER
PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B) EACH PARTY HERETO UNDERSTANDS AND HAS CONSIDERED THE IMPLICATION OF THIS WAIVER, (C)&nbsp;EACH
PARTY HERETO MAKES THIS WAIVER VOLUNTARILY, AND (D)&nbsp;EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.6 <U>Severability</U>. If any term, provision, covenant or restriction of
this Agreement is held by a court of competent jurisdiction or other Governmental Authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and
effect and shall in no way be affected, impaired or invalidated so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such a determination, the parties
hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties hereto as closely as possible in an acceptable manner in order that the transactions contemplated hereby be consummated as originally
contemplated to the fullest extent possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.7 <U>Counterparts</U><U> </U><U>and</U><U> </U><U>Signature</U>. This
Agreement may be signed manually or by facsimile or other electronic transmission by the parties (including in .pdf, .tiff, .jpg or similar format), in any number of counterparts, each of which shall be an original, with the same effect as if the
signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when each party hereto shall have received a counterpart hereof signed by all of the other parties hereto. Until and unless each party has received a
counterpart hereof signed by the other party hereto, this Agreement shall have no effect and no party shall have any right or obligation hereunder (whether by virtue of any other oral or written agreement or other communication). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.8 <U>Termination</U>. This Agreement shall be terminated and be of no force or effect, the parties hereto shall have no
liability hereunder (other than with respect to monies due and owing by Parent to Rights Agent), and no payments shall be required to be made, upon the earliest to occur of (a)&nbsp;the mailing (or payment by other means) by the Rights Agent to the
address of each Holder as reflected in the CVR Register the full amount of all Milestone Payment Amounts required to be paid under the terms of this Agreement, (b)&nbsp;the delivery of a written notice of termination duly executed by Parent and the
Acting Holders, and (c)&nbsp;the occurrence of the last Milestone Outside Date prior to the achievement of the Milestones. Notwithstanding anything in this Agreement to the contrary, no termination of this Agreement shall relieve any party hereto of
any liability for any breach of this Agreement occurring prior to such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.9 <U>Entire</U><U>
</U><U>Agreement</U>. This Agreement (including the schedules hereto) and the Merger Agreement (including the schedules, annexes and exhibits thereto and the documents and instruments referred to therein) constitute the entire agreement between the
parties with respect to the subject matter of this Agreement and supersede all prior agreements and understandings, both oral and written, between the parties with respect to the subject matter of this Agreement. If and to the extent any provision
of this Agreement is inconsistent or conflicts with the Merger Agreement, (a)&nbsp;this Agreement shall govern and be controlling with respect to CVR matters only, and (b)&nbsp;the Merger Agreement shall govern and be controlling with respect to all
matters unrelated to CVRs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.10 <U>Payments on Next Business Day</U>. In the event that a Milestone Payment Date or any
other date by which any payment in respect of the CVRs shall be required to be made hereunder shall not be a Business Day, then, notwithstanding any provision of this Agreement to the contrary, any payment required to be made in respect of the CVRs
on such date need not be made on such date, but may be made on the next Business Day thereafter with the same force and effect as if made on the applicable required date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.11 <U>Confidentiality</U>. The Rights Agent agrees that all books, records,
information and data pertaining to the business of Parent or its Affiliates, including inter alia, personal, <FONT STYLE="white-space:nowrap">non-public</FONT> Holder information, which are exchanged or received pursuant to the negotiation or the
carrying out of this Agreement shall not be used by the Rights Agent for any purpose other than carrying out its duties under this Agreement and shall not be voluntarily disclosed by the Rights Agent to any other Person, including any Holder, except
as may be required by a valid order of any Governmental Authority of competent jurisdiction or is otherwise required by applicable Law, the rules and regulations of the Securities and Exchange Commission or any stock exchange on which the securities
of the Rights Agent are listed, or pursuant to subpoenas from state or federal Governmental Authorities (subject to (x)&nbsp;the Rights Agent notifying, to the extent practicable, Parent of such potential disclosure reasonably in advance of such
disclosure, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(y) cooperating with Parent, at Parent&#8217;s expense, in any effort to restrict disclosure of such book, records, information or data and
(z)&nbsp;the Rights Agent only disclosing such books, records, information or data that is required to be so disclosed by such valid order, such applicable Law, rule or regulation of the Securities and Exchange Commission or any stock exchange on
which the securities of the Rights Agent are listed or such subpoena). This <U>Section</U><U></U><U>&nbsp;6.11</U> shall survive the termination of this Agreement and shall remain in full force and effect in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of page intentionally left blank</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its
behalf by its duly authorized officers as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MANNKIND CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ David Thomson</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David Thomson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Executive Vice President, General Counsel and Secretary</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BROADRIDGE CORPORATE ISSUER SOLUTIONS, LLC solely in its capacity as Rights Agent</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ John P. Dunn</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John P. Dunn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Senior Vice President</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> C<SMALL>ONTINGENT</SMALL> V<SMALL>ALUE</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mnkd-20251007.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 10/10/2025 1:14:49 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:mnkd="http://www.mannkindcorp.com/20251007"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.mannkindcorp.com/20251007"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnkd-20251007_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnkd-20251007_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>mnkd-20251007_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 10/10/2025 1:14:50 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>mnkd-20251007_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 10/10/2025 1:14:50 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mnkd-20251007.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MANNKIND CORP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000899460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  07,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3607736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1 Casper Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Danbury<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(818)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">661-5000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MNKD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d63266d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d63266d8k.htm">d63266d8k.htm</File>
    <File>mnkd-20251007.xsd</File>
    <File>mnkd-20251007_lab.xml</File>
    <File>mnkd-20251007_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d63266d8k.htm": {
   "nsprefix": "mnkd",
   "nsuri": "http://www.mannkindcorp.com/20251007",
   "dts": {
    "inline": {
     "local": [
      "d63266d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "mnkd-20251007.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mnkd-20251007_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mnkd-20251007_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-10-07_to_2025-10-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d63266d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-10-07_to_2025-10-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d63266d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.mannkindcorp.com//20251007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-25-236064-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-236064-xbrl.zip
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M-2L$'V<BT<9N0C\EX!OH<B/A7?$@B"?^O1UX-O.]H8>*PO?LGN>#QZ1]VD4
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MH?R,XB%=[$!U#2)LW#-$-EV@4 4J%:B=)DY!\@&GB0 %^'?2QZ3Z CGD";>
MSO2$:!>4:B7R"I.0[=9@6[!\S$<VZ4W^@/4Z@:CMS*9Q,#SBYB[AR!*25)@6
MC[P8]/SFD<1\'E$-$;C(LVV=0/7 5W<](8%S=POR<[)U(88H=E,4" (-!DGE
M Q4P9X9C=,8G1G@A'YS0J,0+=NLP=L!]DI&E7'R"@84TFFRH -M81@[0L9+[
ME.>)D1P\\(845)3: J=*RL0Q26.EOV MU6]#%%2#--J@,7/,;2()MRCQ0YN
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MSE)0M,# (=%-/%>\&'# CCR$7OF89Y,$Z;442\V0QLJW"WT,D; E4'V6%F=
MED!W\JT$%<Q&5?-R@?N!YW-13"XP2NG<JA43XB3[!.LY+XH1J1&#.6P5[M^Q
M'Z8W@W5<))-8;NJ93-"\*<TOLK+(>0V@5 RM"S>Y2(#()7!.X3D^<QDDFPX6
M9>6CJ^29_8Q&&F_[&.2P_W'M5L@.QWBMG>+E]]"-8^\?KIT#(NA\P;P4BO55
MI&&=P4[PER0GB<SD!U55##,Z#L>VFC,)QVW\R-PWF$JY?(F_N\@P>HJ7+$9O
M#S[H])# *QZSX%)FV=EPW)5VLBH6Y1!>R@(0M'AU*LG;,0A@N(*[L"0 -88"
M]YRCD1IX -K%!\$V03:+XTCP?3'XDRUI8])'K(%M1?MSYXN 80M>GK^"CM%M
MBDI+IY=6M2B ,* NQ<W$KL H<V<C"#,/DDJC1?00F8Z&R[71;.P5;OR"[Y"0
M[8]D(L'-R2/242]@:X1T3-"B>EC#1H)YZ#6E,#72/#!:D(EP4SCN<3=:$7H)
M7\U6.-@:"X[L"G^>S7\0>WVUOG@7,8L=G?EWK^>MZZI$AAQG_DJ"ZVRLH+@'
MO6$^7/[7L#)N>7GLMOEW7.!OQRMLI9*CPB#N-<YBDA5\HD(4Y"DT_,=>9&Z3
M"/%_[[CT$A!41>O.B*ICHX]?1.NW=8U->.BZ#EDXUK4>V9VM)YN#KG?*/LS*
M]DYWFT1P"DO:2\E5@NKK:8E)>WHAQ+D$Q W*5,6Y J -% _J$P@S;OX:]_2V
MEH890RO\Y4'VIE'QX:LK[?6\R!^Q_:#FNAFMBQ84A;C)8Z>!E'@-I=Z&7O):
M4XF#=S;SBX.O_P1=>!Z!B8FV'%C*%;KCT?T'5!MK*G)]>_1C'1MCXY+7*!]U
M-AKYS$C[_#;V>\K'L%GCK)R"^0'&#)K,SN%(&@H8?.B.5%N'[/6B/ ,Z_%_G
MXZ:TL.5#BO/^OQ:X4A)TG0UF_.WBP03?*: .=G8^;PD@WB#1[B$YX-N]GEEG
M9\,O-$SY>(MF&DY_KUR<1;T1&(X@#TIWH.NXXL,<Z3OT))#7 1-&.,+5PDDZ
M&T%$Y\S]*C;1M> +=';\:Y%4V:/@0PZ=&:_'G#Q/@V($_W^4XJ7E8=',SR2(
M#';R*+O(^(^!)+"8S45'(+"BH810T&G#;Z.Q-X=F@F"NE^CG*;/!(L<Y_@GW
MG9P)/ 4ZHR@I!QF.C)%F_$3^Q(L(5)E.Z+G-D1GW6JS4;H0RU"J=C!]9UQPM
M)#9A:O31D=UN-X4FJL=%V8"4A@KWS1V41L!AGBXJ7BUF<!,E02B._+_&*=KD
M\ _FC)CTO\C))[C(R8<VB=G/0ME([+[002?%$#\:%4!E\VR(4T.##F0GYTBP
M!ZO(1NIE'A6+ 1Q".^V%C@RX>>+*TZAORVN$C-A!(GM)>56D?/T)^UC!(3,?
MO9 $>DQ<Y*T;"1%V-H!PTOP,O3.S!>\K^S=CX]R<X\O1CQ0X2V/O_<" 7D7T
MQ;>>XTT@#-A)*ZX]>.\4$[HX^Y__->9\"G;P/*C>OXJU:\X;TMOE>5&E0$&8
M/4VY41EFDK+^Z^/>5BO6A"WC\D/?TX-J3ON'>VUJDWBLLC/-I<OAQR-DZC)Y
M(B;@2U*8(28*4JM-4][9CG:WWFX=;T7_^1_;SW]Z^61[)V)O!UXPC.(,74;V
M< +\#"X2\B:LPZ%HS"PHSG'./]G<0/@\I!39!ZXPXGN\*UDR*PQAL.;^WW.=
M/?GN.KLKNOM3,L2:\3NCC>+%?31*+[)A:E-#W'5"'1UD!%!D9^/GQ]'T[,?M
MZ4'T]N/QT<GN_O^\.OGHEN;G^=,SF#8($[J8CV@S7L"*87; !(&^X$>OH\WQ
MH@0N.87+ 50M<^URL8A6: "U Q/:?O;SXZ<_@5R=5$7T"92&')^Z4JLXV?WP
M:'M[.U9M8I1.0!M"_IMF)"TQ])"CIE#P^PM76_,[\+?.1JWZ[Y&/YYZ@8K*'
M/-[-7(<''78)#'WZL"RG:3DT3Y^4HM#!2EI"9P.D%:8%P^8<+5Q%C!WM(>V-
M@^3RW\H_8?Q\[3<4;&.,IIH:)4RK0QK$2''$_@T\I9:@*BM.48,7/*@&93R9
M+<G,="LI,2Z;<#5@COK^G"N]T@G\9W-[I_MH"B\[QQR-#.S*E,.9+N&,ZQ35
M8;&7@BKA:L&?;(,ZN_-XYWG<5OSE,DG^MKW].'[\F/Z/DN.*<C*Z1&YUF,ZC
MDV225IH$]<$$XIG85LSS+T)HAP5PM-O*C-W9>@IFU9<GQ][1ZJ*]6J[\ R[Q
MUN\-L&4,%#?6R$S#6;EK0@IQ](]%GLJ%>$SEY#^]#(N*:[_N;)A[&S?O% [Q
M_"$%0R/'H+$S:TNIGM_%X<%1K OLQ-%FUL7"\9^>->HH@1..@R 02&7A5>1N
M/<&R*3R!2,[O.8[&PSU[W#J</<+&>'J@D9XE.S)@2!YSY^937$5BJVGD;@YA
MT.ULK#Z%'3X%5 6Y)I8+-^&9]E6[6ME5]<-_V]ZY4G+4I=Q*R>9$VNKSD?N:
MC6,IK+:/6E%WGIV=XP*N,Z$KU>OM'9ZH2U;D^5["'CF4E4"&XFSMUB"0AF(3
MZ):"GCU<<*(R9NIACEF"T=1'F.^$B3A 86[PQUO;,BJ>DV0OD9^+@OWUL4$?
M*#&SN;+UN)2R7*W8$7Z>@2>"I2!MF)6L=^7EA5NF2YTB+(QL?--3 =;UA<>"
MN:,^4]TNYB$-E69:6(^N8%,MY++J)#K#7$@)H;#SLZ:^R1-^Y,V,E#K8>"S6
MNIJNX3>/YA0$E0V4F3FN0*G!8AV'/N7 ?==<VUBS^?U7@<#% ?(%75R-#2'O
MP:1+Q[9JOS]/)[XN57>%JM8GG)E8M+D:B4D\>P&$/-N:;L51/\'/<_(XQOJ3
MUJ48W:IE.7\1!5#W^R^D =[V&EO,^37Y(M^N=_#I=^_@W7#>PR!JZT(8UW?E
M<W;YSG;T<>MD:W>KL_'DR3/@9,05$O4^P/.26XX4Z;.38;H(Y(,O^JNZ[9T,
M;G?*Y/ U1J\JY,Z8OBS5CICQ%CIF% X$GT;_8JV(ZD,MB3\,FC.<2\D)'1DK
M!*_V7P] <XG&J"J\^G'_=5).7:'5A()T0957S#Y5EZO=S+AN1T,@Z8JR!'4E
M_AVQ>UE?9X,7Z&N\%B.:^MCA,E"\E++;MB@GRNV4VSVO$3GQ>E86H*;PMS#A
M1<7D!'HP"AWX]4*710Y,(4FJY9A+<OZ$ J4+Q&U!K_&DN,1_8"D)Q89G2<:9
M".CD=-7*-#OR#\=2;^/F-BB*3Q[_H;-1.^%K;J@HJ,E:+)?K&$"_?(D5"A0Q
M2BGM@"=-%Q(3$($>::[56KRLNYG7 &LI!TCI,:;6EV?PQ_!3%8=U&Q6&X#EF
MK15-+FN20.<*H!6@E[(RQ3LNT%R46,S.KGR\0;80:0YJ-?P,M,O!8HF'!<2W
MF 5UMO0)!BX1$0T_L*E'%2+ZI<D$2R\2*H3!RC.D OBSS%+SZJ7#_3'5^IP
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M ?!08<>3T6R-?T(%T03<"(_'3A=NNLE()21Y8@LV)>V+9O"(9T#+\GJ>E%4
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M,?=]D K ASOVR$47N;>]=BPFJ1>\AA0828G0,1,$;,#*TVPD;6AS/^"<$&!
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M!Y@P3RXM!.CF3M* (E.7>HH4IFUD!)\^Q!BI%V<!(ZRD2>!*[=41OO!;_;L
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MG >R81;ZF++N#,$CH"&HK<W)949(/_CI#',/&3^0RQ(X,PX-Q5$RI?3_!.9
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M G_AR=93_#O -FZ?VX/@R@3$<\;%W=ITI/#WV^.%4$C3,$Z._\FGKNHX:?I
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M/>3F ,;U $4;F0"5UXXF7N^)_X*M^=)]>;7O*C* E^V_)E)H RMWJ)J8.;?
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M&<US:-T><D29UE:;GXW.$KR9JHV7%"H.M;-9B7[%(?NC];I)SL*LF/.E5\+
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M>KL2F.#1WA_PX?O37P]>__]02P,$%     @ *8I)6_FA@&E  P  5PL  !$
M  !M;FMD+3(P,C4Q,# W+GAS9+U6[T_;/!#^/FG_PRV?WDEOXJ:,38TH$WL9
M$A)C4\>F?9O<Y%HL'#NS':#__7MVDI(6VA68ABKA^NZY>^ZG>_#^MI1PC<8*
MK<91F@PB0)7K0JCY.*IMS&TN1/3^\.6+@U=Q#,<GI^<0PZ5SE<T8N[FY28J9
M4%;+VI$%F^2Z9!#'G?Y_%]_@>V,]@PE*Y!9AN)\.X4,M9)$-!\/]P;OA,$G[
M((/<6X.".\P@'3#Z>$U(L_1-]F8$1Y_@([<.C8(+46(?JZN%$?-+!__DKR&
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MVH'\#[XL^Y&GFZ,8HG,>L4_KY8S)9A-3S.MT/"P&T'[>'?S'6K24&W5(Y8F
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M!?;IR?41^V*?!<22OP!02P$"% ,4    "  IBDE;$%7MN>$D  #OT0  #0
M            @ $     9#8S,C8V9#AK+FAT;5!+ 0(4 Q0    ( "F*25M^
M_$R"WV@  -KI 0 0              "  0PE  !D-C,R-C9D97@Q,#$N:'1M
M4$L! A0#%     @ *8I)6_FA@&E  P  5PL  !$              ( !&8X
M &UN:V0M,C R-3$P,#<N>'-D4$L! A0#%     @ *8I)6XY$]D]@!@  O4,
M !4              ( !B)$  &UN:V0M,C R-3$P,#=?;&%B+GAM;%!+ 0(4
M Q0    ( "F*25M@OD7CN00  (,J   5              "  1N8  !M;FMD
G+3(P,C4Q,# W7W!R92YX;6Q02P4&      4 !0 ^ 0  !YT

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>d63266d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mnkd-20251007.xsd" xlink:type="simple"/>
    <context id="duration_2025-10-07_to_2025-10-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
        </entity>
        <period>
            <startDate>2025-10-07</startDate>
            <endDate>2025-10-07</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2025-10-07_to_2025-10-07"
      id="Hidden_dei_EntityRegistrantName">MANNKIND CORP</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-402">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-10-07_to_2025-10-07"
      id="Hidden_dei_EntityCentralIndexKey">0000899460</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-413">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-414">2025-10-07</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-415">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-416">000-50865</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-417">13-3607736</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-418">1 Casper Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-419">Danbury</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-420">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-421">06810</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-422">(818)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-423">661-5000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-424">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-425">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-426">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-427">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-428">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-429">MNKD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-430">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-10-07_to_2025-10-07" id="ixv-431">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
